1
|
Nasr AA, Fund X, Barreau S, Desterke C, Borie C, Oudrhiri N, Faivre J, Bennaceur-Griscelli A, Turhan AG. BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2024; 65:692-695. [PMID: 38293748 DOI: 10.1080/10428194.2024.2308665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Accepted: 01/17/2024] [Indexed: 02/01/2024]
Affiliation(s)
- Amen Allah Nasr
- APHP-Paris Saclay, Service d'Hématologie-Bicêtre, Kremlin-Bicêtre, France
- Faculté de Médecine Paris-Saclay, Université Paris-Saclay, Kremlin-Bicêtre, France
- Inserm UMR-S 1310, Villejuif, France
| | - Xavier Fund
- Inserm UMR-S 1310, Villejuif, France
- APHP Paris Saclay Service d'Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, France
| | - Sylvain Barreau
- APHP-Paris Saclay, Service d'Hématologie-Bicêtre, Kremlin-Bicêtre, France
- Inserm UMR-S 1310, Villejuif, France
| | - Christophe Desterke
- Faculté de Médecine Paris-Saclay, Université Paris-Saclay, Kremlin-Bicêtre, France
- Inserm UMR-S 1310, Villejuif, France
| | - Claire Borie
- Inserm UMR-S 1310, Villejuif, France
- APHP Paris Saclay Service d'Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, France
| | - Noufissa Oudrhiri
- APHP-Paris Saclay, Service d'Hématologie-Bicêtre, Kremlin-Bicêtre, France
- Inserm UMR-S 1310, Villejuif, France
- APHP Paris Saclay Service d'Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, France
| | - Jamila Faivre
- APHP Paris Saclay Service d'Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, France
| | - A Bennaceur-Griscelli
- APHP-Paris Saclay, Service d'Hématologie-Bicêtre, Kremlin-Bicêtre, France
- Faculté de Médecine Paris-Saclay, Université Paris-Saclay, Kremlin-Bicêtre, France
- Inserm UMR-S 1310, Villejuif, France
- APHP Paris Saclay Service d'Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, France
- Centre for iPSC Therapies (CITHERA) INSERM UMS 45, GenopoleEvry, France
| | - A G Turhan
- APHP-Paris Saclay, Service d'Hématologie-Bicêtre, Kremlin-Bicêtre, France
- Faculté de Médecine Paris-Saclay, Université Paris-Saclay, Kremlin-Bicêtre, France
- Inserm UMR-S 1310, Villejuif, France
- APHP Paris Saclay Service d'Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, France
- Centre for iPSC Therapies (CITHERA) INSERM UMS 45, GenopoleEvry, France
- Department of Hematology, American Hospital of Paris, Neuilly Sur Seine, France
| |
Collapse
|
2
|
Chaker D, Desterke C, Moniaux N, Bani MA, Oudrhiri N, Faivre J, Turhan AG, Bennaceur-Griscelli A, Griscelli F. Direct Reprogramming of Hepatocytes Into JAK/Stat-Dependent LGR5+ Liver Cells Able to Initiate Intrahepatic Cholangiocarcinoma. Stem Cells 2024; 42:301-316. [PMID: 38262709 DOI: 10.1093/stmcls/sxae006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Accepted: 12/18/2023] [Indexed: 01/25/2024]
Abstract
Somatic cells that have been partially reprogrammed by the factors Oct4, Sox2, Klf4, and cMyc (OSKM) have been demonstrated to be potentially tumorigenic in vitro and in vivo due to the acquisition of cancer-associated genomic alterations and the absence of OSKM clearance over time. In the present study, we obtained partially reprogrammed, SSEA1-negative cells by transducing murine hepatocytes with Δ1Δ3-deleted adenoviruses that expressed the 4 OSKM factors. We observed that, under long-term 2D and 3D culture conditions, hepatocytes could be converted into LGR5-positive cells with self-renewal capacity that was dependent on 3 cross-signaling pathways: IL6/Jak/Stat3, LGR5/R-spondin, and Wnt/β-catenin. Following engraftment in syngeneic mice, LGR5-positive cells that expressed the cancer markers CD51, CD166, and CD73 were capable of forming invasive and metastatic tumors reminiscent of intrahepatic cholangiocarcinoma (ICC): they were positive for CK19 and CK7, featured associations of cord-like structures, and contained cuboidal and atypical cells with dissimilar degrees of pleomorphism and mitosis. The LGR5+-derived tumors exhibited a highly vascularized stroma with substantial fibrosis. In addition, we identified pro-angiogenic factors and signaling pathways involved in neo-angiogenesis and vascular development, which represent potential new targets for anti-angiogenic strategies to overcome tumor resistance to current ICC treatments.
Collapse
Affiliation(s)
- Diana Chaker
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Université Paris Saclay, Villejuif, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMS 045 - CITHERA "Center for iPSC Cell Therapy," Genopole, National Infrastructure INGESTEM, Corbeil-Essonnes, Evry.France
| | - Christophe Desterke
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Université Paris Saclay, Villejuif, France
- Université Paris-Saclay, Faculté de Médecine Kremlin Bicêtre, France
| | - Nicolas Moniaux
- Université Paris-Saclay, Faculté de Médecine Kremlin Bicêtre, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS1193, Villejuif, France
| | - Mohamed-Amine Bani
- Institut Gustave-Roussy, Département de Biologie et Pathologie Médicale, service de pathologie morphologique, Villejuif, France
- Gustave Roussy Cancer Centre, Université Paris-Saclay, Inserm US23, CNRS, AMMICa, Villejuif, France
| | - Noufissa Oudrhiri
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Université Paris Saclay, Villejuif, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMS 045 - CITHERA "Center for iPSC Cell Therapy," Genopole, National Infrastructure INGESTEM, Corbeil-Essonnes, Evry.France
- Service d'Hématologie Biologique Laboratoire d'Onco-Hematologie moleculaire et Cytogénetique APHP, Hôpital Universitaire Paris Sud Paul-Brousse, Villejuif, France
| | - Jamila Faivre
- Université Paris-Saclay, Faculté de Médecine Kremlin Bicêtre, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS1193, Villejuif, France
- Service d'Hématologie Biologique Laboratoire d'Onco-Hematologie moleculaire et Cytogénetique APHP, Hôpital Universitaire Paris Sud Paul-Brousse, Villejuif, France
| | - Ali G Turhan
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Université Paris Saclay, Villejuif, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMS 045 - CITHERA "Center for iPSC Cell Therapy," Genopole, National Infrastructure INGESTEM, Corbeil-Essonnes, Evry.France
- Université Paris-Saclay, Faculté de Médecine Kremlin Bicêtre, France
- Service d'Hématologie Biologique Laboratoire d'Onco-Hematologie moleculaire et Cytogénetique APHP, Hôpital Universitaire Paris Sud Paul-Brousse, Villejuif, France
- Service d'Hématologie Biologique, Hôpital Universitaire Paris Sud, (AP-HP) 94 Kremlin Bicêtre, France
| | - Annelise Bennaceur-Griscelli
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Université Paris Saclay, Villejuif, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMS 045 - CITHERA "Center for iPSC Cell Therapy," Genopole, National Infrastructure INGESTEM, Corbeil-Essonnes, Evry.France
- Université Paris-Saclay, Faculté de Médecine Kremlin Bicêtre, France
- Service d'Hématologie Biologique Laboratoire d'Onco-Hematologie moleculaire et Cytogénetique APHP, Hôpital Universitaire Paris Sud Paul-Brousse, Villejuif, France
| | - Frank Griscelli
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Université Paris Saclay, Villejuif, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMS 045 - CITHERA "Center for iPSC Cell Therapy," Genopole, National Infrastructure INGESTEM, Corbeil-Essonnes, Evry.France
- Institut Gustave-Roussy, Département de Biologie et Pathologie Médicale, service de pathologie morphologique, Villejuif, France
- Université Paris Descartes, Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France
| |
Collapse
|
3
|
Marcoux P, Hwang JW, Desterke C, Imeri J, Bennaceur-Griscelli A, Turhan AG. Modeling RET-Rearranged Non-Small Cell Lung Cancer (NSCLC): Generation of Lung Progenitor Cells (LPCs) from Patient-Derived Induced Pluripotent Stem Cells (iPSCs). Cells 2023; 12:2847. [PMID: 38132167 PMCID: PMC10742233 DOI: 10.3390/cells12242847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 12/03/2023] [Accepted: 12/08/2023] [Indexed: 12/23/2023] Open
Abstract
REarranged during Transfection (RET) oncogenic rearrangements can occur in 1-2% of lung adenocarcinomas. While RET-driven NSCLC models have been developed using various approaches, no model based on patient-derived induced pluripotent stem cells (iPSCs) has yet been described. Patient-derived iPSCs hold great promise for disease modeling and drug screening. However, generating iPSCs with specific oncogenic drivers, like RET rearrangements, presents challenges due to reprogramming efficiency and genotypic variability within tumors. To address this issue, we aimed to generate lung progenitor cells (LPCs) from patient-derived iPSCs carrying the mutation RETC634Y, commonly associated with medullary thyroid carcinoma. Additionally, we established a RETC634Y knock-in iPSC model to validate the effect of this oncogenic mutation during LPC differentiation. We successfully generated LPCs from RETC634Y iPSCs using a 16-day protocol and detected an overexpression of cancer-associated markers as compared to control iPSCs. Transcriptomic analysis revealed a distinct signature of NSCLC tumor repression, suggesting a lung multilineage lung dedifferentiation, along with an upregulated signature associated with RETC634Y mutation, potentially linked to poor NSCLC prognosis. These findings were validated using the RETC634Y knock-in iPSC model, highlighting key cancerous targets such as PROM2 and C1QTNF6, known to be associated with poor prognostic outcomes. Furthermore, the LPCs derived from RETC634Y iPSCs exhibited a positive response to the RET inhibitor pralsetinib, evidenced by the downregulation of the cancer markers. This study provides a novel patient-derived off-the-shelf iPSC model of RET-driven NSCLC, paving the way for exploring the molecular mechanisms involved in RET-driven NSCLC to study disease progression and to uncover potential therapeutic targets.
Collapse
Affiliation(s)
- Paul Marcoux
- INSERM UMR-S-1310, Université Paris Saclay, 94800 Villejuif, France; (P.M.); (J.W.H.); (C.D.); (J.I.); (A.B.-G.)
- Faculty of Medicine, Paris-Saclay University, 94270 Le Kremlin Bicetre, France
| | - Jin Wook Hwang
- INSERM UMR-S-1310, Université Paris Saclay, 94800 Villejuif, France; (P.M.); (J.W.H.); (C.D.); (J.I.); (A.B.-G.)
- Faculty of Medicine, Paris-Saclay University, 94270 Le Kremlin Bicetre, France
| | - Christophe Desterke
- INSERM UMR-S-1310, Université Paris Saclay, 94800 Villejuif, France; (P.M.); (J.W.H.); (C.D.); (J.I.); (A.B.-G.)
- Faculty of Medicine, Paris-Saclay University, 94270 Le Kremlin Bicetre, France
| | - Jusuf Imeri
- INSERM UMR-S-1310, Université Paris Saclay, 94800 Villejuif, France; (P.M.); (J.W.H.); (C.D.); (J.I.); (A.B.-G.)
- Faculty of Medicine, Paris-Saclay University, 94270 Le Kremlin Bicetre, France
| | - Annelise Bennaceur-Griscelli
- INSERM UMR-S-1310, Université Paris Saclay, 94800 Villejuif, France; (P.M.); (J.W.H.); (C.D.); (J.I.); (A.B.-G.)
- Faculty of Medicine, Paris-Saclay University, 94270 Le Kremlin Bicetre, France
- APHP Paris Saclay, Department of Hematology, Hôpital Bicêtre, 94270 Le Kremlin Bicetre, France
- Center for IPSC Therapies, CITHERA, INSERM UMS-45, Genopole Campus, 91100 Evry, France
- APHP Paris Saclay, Department of Hematology, Hôpital Paul Brousse, 94800 Villejuif, France
| | - Ali G. Turhan
- INSERM UMR-S-1310, Université Paris Saclay, 94800 Villejuif, France; (P.M.); (J.W.H.); (C.D.); (J.I.); (A.B.-G.)
- Faculty of Medicine, Paris-Saclay University, 94270 Le Kremlin Bicetre, France
- APHP Paris Saclay, Department of Hematology, Hôpital Bicêtre, 94270 Le Kremlin Bicetre, France
- Center for IPSC Therapies, CITHERA, INSERM UMS-45, Genopole Campus, 91100 Evry, France
- APHP Paris Saclay, Department of Hematology, Hôpital Paul Brousse, 94800 Villejuif, France
| |
Collapse
|
4
|
Boucher L, Sorel N, Desterke C, Chollet M, Rozalska L, Gallego Hernanz MP, Cayssials E, Raimbault A, Bennaceur-Griscelli A, Turhan AG, Chomel JC. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis. Int J Mol Sci 2023; 24:15441. [PMID: 37895120 PMCID: PMC10607477 DOI: 10.3390/ijms242015441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 10/19/2023] [Accepted: 10/20/2023] [Indexed: 10/29/2023] Open
Abstract
Acute myeloid leukemia (AML) with BCR::ABL1 has recently been recognized as a distinct subtype in international classifications. Distinguishing it from myeloid blast crisis chronic myeloid leukemia (BC-CML) without evidence of a chronic phase (CP), remains challenging. We aimed to better characterize this entity by integrating clonal architecture analysis, mutational landscape assessment, and gene expression profiling. We analyzed a large retrospective cohort study including CML and AML patients. Two AML patients harboring a BCR::ABL1 fusion were included in the study. We identified BCR::ABL1 fusion as a primary event in one patient and a secondary one in the other. AML-specific variants were identified in both. Real-time RT-PCR experiments demonstrated that CD25 mRNA is overexpressed in advanced-phase CML compared to AML. Unsupervised principal component analysis showed that AML harboring a BCR::ABL1 fusion was clustered within AML. An AML vs. myeloid BC-CML differential expression signature was highlighted, and while ID4 (inhibitor of DNA binding 4) mRNA appears undetectable in most myeloid BC-CML samples, low levels are detected in AML samples. Therefore, CD25 and ID4 mRNA expression might differentiate AML with BCR::ABL1 from BC-CML and assign it to the AML group. A method for identifying this new WHO entity is then proposed. Finally, the hypothesis of AML with BCR::ABL1 arising from driver mutations on a BCR::ABL1 background behaving as a clonal hematopoiesis mutation is discussed. Validation of our data in larger cohorts and basic research are needed to better understand the molecular and cellular aspects of AML with a BCR::ABL1 entity.
Collapse
MESH Headings
- Humans
- Blast Crisis/genetics
- Fusion Proteins, bcr-abl/genetics
- Fusion Proteins, bcr-abl/metabolism
- Retrospective Studies
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism
- Leukemia, Myeloid, Acute/diagnosis
- Leukemia, Myeloid, Acute/genetics
- RNA, Messenger
Collapse
Affiliation(s)
- Lara Boucher
- CHU de Poitiers, Service de Cancérologie Biologique, F86000 Poitiers, France; (L.B.); (N.S.); (A.R.)
| | - Nathalie Sorel
- CHU de Poitiers, Service de Cancérologie Biologique, F86000 Poitiers, France; (L.B.); (N.S.); (A.R.)
| | - Christophe Desterke
- Faculté de Médecine, Université Paris Saclay, F94270 Le Kremlin-Bicêtre, France; (C.D.); (A.B.-G.); (A.G.T.)
| | - Mélanie Chollet
- CHU de Poitiers, Service d’Hématologie Biologique, F86000 Poitiers, France; (M.C.); (L.R.)
| | - Laura Rozalska
- CHU de Poitiers, Service d’Hématologie Biologique, F86000 Poitiers, France; (M.C.); (L.R.)
| | - Maria Pilar Gallego Hernanz
- CHU de Poitiers, Service d’Oncologie Hématologique et Thérapie Cellulaire, F86000 Poitiers, France; (M.P.G.H.); (E.C.)
- INSERM, CIC-P 1402, F86000 Poitiers, France
| | - Emilie Cayssials
- CHU de Poitiers, Service d’Oncologie Hématologique et Thérapie Cellulaire, F86000 Poitiers, France; (M.P.G.H.); (E.C.)
- INSERM, CIC-P 1402, F86000 Poitiers, France
| | - Anna Raimbault
- CHU de Poitiers, Service de Cancérologie Biologique, F86000 Poitiers, France; (L.B.); (N.S.); (A.R.)
- CHU de Poitiers, Service d’Hématologie Biologique, F86000 Poitiers, France; (M.C.); (L.R.)
| | - Annelise Bennaceur-Griscelli
- Faculté de Médecine, Université Paris Saclay, F94270 Le Kremlin-Bicêtre, France; (C.D.); (A.B.-G.); (A.G.T.)
- INSERM U1310, F94807 Villejuif, France
- INGESTEM-ESTeam Paris Sud, F94800 Villejuif, France
- Service d’Onco-Hématologie, Hôpital Paul Brousse, AP-HP Université Paris Saclay, F94804 Villejuif, France
- Service d’Hématologie, Hôpital Bicêtre, AP-HP Université Paris Saclay, F94270 Le Kremlin-Bicêtre, France
| | - Ali G. Turhan
- Faculté de Médecine, Université Paris Saclay, F94270 Le Kremlin-Bicêtre, France; (C.D.); (A.B.-G.); (A.G.T.)
- INSERM U1310, F94807 Villejuif, France
- INGESTEM-ESTeam Paris Sud, F94800 Villejuif, France
- Service d’Onco-Hématologie, Hôpital Paul Brousse, AP-HP Université Paris Saclay, F94804 Villejuif, France
- Service d’Hématologie, Hôpital Bicêtre, AP-HP Université Paris Saclay, F94270 Le Kremlin-Bicêtre, France
| | - Jean-Claude Chomel
- CHU de Poitiers, Service de Cancérologie Biologique, F86000 Poitiers, France; (L.B.); (N.S.); (A.R.)
- INSERM U1310, F94807 Villejuif, France
| |
Collapse
|
5
|
Artus J, Zenych A, Simanic I, Desterke C, Clay D, Saïm S, Ijjeh Y, de Souza LEB, Coignard S, Bennaceur-Griscelli A, Turhan AG, Foudi A. BCR-ABL promotes hematopoietic stem and progenitor cell formation in embryonic stem cells. Exp Hematol 2023:S0301-472X(23)00254-0. [PMID: 37331423 DOI: 10.1016/j.exphem.2023.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 05/30/2023] [Accepted: 06/12/2023] [Indexed: 06/20/2023]
Abstract
Generating Hematopoietic Stem Cells (HSCs) from Pluripotent Stem Cells (PSCs) has been a long-lasting quest in the field of hematopoiesis. Previous studies suggested that enforced expression of BCR-ABL, the unique oncogenic driver of Chronic Myelogeneous Leukemia (CML), in Embryonic Stem Cells (ESCs)-derived hematopoietic cells is sufficient to confer long-term in vivo repopulating potential. To precisely uncover the molecular events regulated by the Tyrosine-kinase activity of BCR-ABL1 (p210) during the course of hematopoietic differentiation, we engineered a Tet-ON inducible system to modulate its expression in murine ESC. We showed in unique site-directed knock-in ESC model, that BCR-ABL expression tightly regulated by doxycycline (dox) controls the formation and the maintenance of immature hematopoietic progenitors. Interestingly, these progenitors can be expanded in vitro for several passages in the presence of dox. Our analysis of cell surface markers and transcriptome compared to wild-type fetal and adult HSCs unraveled a similar molecular signature. LTC-IC assay confirmed their self-renewal capacities albeit with a differentiation bias towards erythroid and myeloid cells. Collectively, our novel Tet-ON system represents a unique in vitro model to shed lights on ESC-derived hematopoiesis, CML initiation and maintenance.
Collapse
Affiliation(s)
- Jérôme Artus
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France.
| | - Alina Zenych
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Isidora Simanic
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir / INSERM UMRS-1310 Paris Saclay University, Villejuif, France
| | - Christophe Desterke
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France; INGESTEM National iPSC Infrastructure, Villejuif, France; CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Paris Saclay University Genopole, Evry, France
| | - Denis Clay
- INSERM UMS-44, Paris Saclay University, Villejuif, France
| | - Sonia Saïm
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Yousef Ijjeh
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir / INSERM UMRS-1310 Paris Saclay University, Villejuif, France
| | - Lucas Eduardo Botelho de Souza
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir / INSERM UMRS-1310 Paris Saclay University, Villejuif, France
| | - Sabrina Coignard
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir / INSERM UMRS-1310 Paris Saclay University, Villejuif, France
| | - Annelise Bennaceur-Griscelli
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France; APHP Paris Saclay, Department of Hematology, Hôpital Bicêtre and Paul Brousse, Villejuif, France; INGESTEM National iPSC Infrastructure, Villejuif, France; CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Paris Saclay University Genopole, Evry, France
| | - Ali G Turhan
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France; APHP Paris Saclay, Department of Hematology, Hôpital Bicêtre and Paul Brousse, Villejuif, France; INGESTEM National iPSC Infrastructure, Villejuif, France; CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Paris Saclay University Genopole, Evry, France
| | - Adlen Foudi
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France; ATIP/Avenir / INSERM UMRS-1310 Paris Saclay University, Villejuif, France.
| |
Collapse
|
6
|
Baykal S, Voldoire M, Desterke C, Sorel N, Cayssials E, Johnson-Ansah H, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG. ENOX2 NADH Oxidase: A BCR-ABL1-Dependent Cell Surface and Secreted Redox Protein in Chronic Myeloid Leukemia. Turk J Haematol 2023; 40:101-117. [PMID: 37026766 PMCID: PMC10240159 DOI: 10.4274/tjh.galenos.2023.2022-0339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Accepted: 04/06/2023] [Indexed: 04/08/2023] Open
Abstract
Objective Chronic myeloid leukemia (CML) is a disease caused by the acquisition of BCR-ABL1 fusion in hematopoietic stem cells. In this study, we focus on the oncofetal ENOX2 protein as a potential secretable biomarker in CML. Materials and Methods We used cell culture, western blot, quantitative RT-PCR, ELISA, transcriptome analyses, and bioinformatics techniques to investigate ENOX2 mRNA and protein expression. Results Western blot analyses of UT-7 and TET-inducible Ba/F3 cell lines demonstrated the upregulation of the ENOX2 protein. BCR-ABL1 was found to induce ENOX2 overexpression in a kinase-dependent manner. We confirmed increased ENOX2 mRNA expression in a cohort of CML patients at diagnosis. In a series of CML patients, ELISA assays showed a highly significant increase of ENOX2 protein levels in the plasma of patients with CML compared to controls. Reanalyzing the transcriptomic dataset confirmed ENOX2 mRNA overexpression in the chronic phase of the disease. Bioinformatic analyses identified several genes whose mRNA expressions were positively correlated with ENOX2 in the context of BCR-ABL1. Some of them encode proteins involved in cellular functions compatible with the growth deregulation observed in CML. Conclusion Our results highlight the upregulation of a secreted redox protein in a BCR-ABL1-dependent manner in CML. The data presented here suggest that ENOX2, through its transcriptional mechanism, plays a significant role in BCR-ABL1 leukemogenesis.
Collapse
Affiliation(s)
- Seda Baykal
- İzmir Biomedicine and Genome Center, İzmir, Türkiye
- Dokuz Eylül University Faculty of Medicine, Department of Medical Biology, İzmir, Türkiye
| | - Maud Voldoire
- CHD La Roche-sur-Yon-Service de Médecine Onco-Hématologie, La Roche-sur-Yon, Pays de la Loire, France
| | - Christophe Desterke
- Université Paris-Saclay BU Kremlin-Bicêtre-Faculté de Médecine, Le Kremlin-Bicetre, Île-de-France
| | - Nathalie Sorel
- CHU Poitiers-Service de Cancérologie Biologique, Poitiers, France
| | - Emilie Cayssials
- CHU Poitiers-Service d’Oncologie Hématologique et Thérapie Cellulaire, Poitiers, France
| | | | | | | | | | - Ali G. Turhan
- Paris-Saclay University-Service d'hematologie, Hopital Bicetre, Paris, Villejuif, France
| |
Collapse
|
7
|
Telliam G, Desterke C, Imeri J, M'kacher R, Oudrhiri N, Balducci E, Fontaine-Arnoux M, Acloque H, Bennaceur-Griscelli A, Turhan AG. Modeling Global Genomic Instability in Chronic Myeloid Leukemia (CML) Using Patient-Derived Induced Pluripotent Stem Cells (iPSCs). Cancers (Basel) 2023; 15:cancers15092594. [PMID: 37174060 PMCID: PMC10177163 DOI: 10.3390/cancers15092594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 04/18/2023] [Accepted: 04/27/2023] [Indexed: 05/15/2023] Open
Abstract
METHODS We used a patient-specific induced pluripotent stem cell (iPSC) line treated with the mutagenic agent N-ethyl-N-nitrosourea (ENU). Genomic instability was validated using γ-H2AX and micronuclei assays and CGH array for genomic events. RESULTS An increased number of progenitors (x5-Fold), which proliferated in liquid cultures with a blast cell morphology, was observed in the mutagenized condition as compared to the unmutagenized one. CGH array performed for both conditions in two different time points reveals several cancer genes in the ENU-treated condition, some known to be altered in leukemia (BLM, IKZF1, NCOA2, ALK, EP300, ERG, MKL1, PHF6 and TET1). Transcriptome GEO-dataset GSE4170 allowed us to associate 125 of 249 of the aberrations that we detected in CML-iPSC with the CML progression genes already described during progression from chronic and AP to BC. Among these candidates, eleven of them have been described in CML and related to tyrosine kinase inhibitor resistance and genomic instability. CONCLUSIONS These results demonstrated that we have generated, for the first time to our knowledge, an in vitro genetic instability model, reproducing genomic events described in patients with BC.
Collapse
Affiliation(s)
- Gladys Telliam
- INSERM UMR_S_1310, Université Paris Saclay, 94800 Villejuif, France
- Faculté de Médecine Paris Saclay, Université Paris Saclay, 94270 Le Kremlin-Bicêtre, France
| | - Christophe Desterke
- INSERM UMR_S_1310, Université Paris Saclay, 94800 Villejuif, France
- Faculté de Médecine Paris Saclay, Université Paris Saclay, 94270 Le Kremlin-Bicêtre, France
| | - Jusuf Imeri
- INSERM UMR_S_1310, Université Paris Saclay, 94800 Villejuif, France
| | - Radhia M'kacher
- APHP Paris Saclay Service d'Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse, 94800 Villejuif, France
| | - Noufissa Oudrhiri
- INSERM UMR_S_1310, Université Paris Saclay, 94800 Villejuif, France
- APHP Paris Saclay Service d'Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse, 94800 Villejuif, France
| | - Estelle Balducci
- INSERM UMR_S_1310, Université Paris Saclay, 94800 Villejuif, France
- Faculté de Médecine Paris Saclay, Université Paris Saclay, 94270 Le Kremlin-Bicêtre, France
- APHP Paris Saclay Service d'Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse, 94800 Villejuif, France
| | - Micheline Fontaine-Arnoux
- APHP Paris Saclay Service d'Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse, 94800 Villejuif, France
| | - Hervé Acloque
- INSERM UMR_S_1310, Université Paris Saclay, 94800 Villejuif, France
| | - Annelise Bennaceur-Griscelli
- INSERM UMR_S_1310, Université Paris Saclay, 94800 Villejuif, France
- Faculté de Médecine Paris Saclay, Université Paris Saclay, 94270 Le Kremlin-Bicêtre, France
- APHP Paris Saclay Service d'Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse, 94800 Villejuif, France
- APHP-Paris Saclay Service d'Hématologie-Bicêtre, 94270 Le Kremlin Bicêtre, France
- INGESTEM National iPSC Infrastructure, 94800 Villejuif, France
- Centre for iPSC Therapies (CITHERA) INSERM UMS 45, Génopole, 91100 Evry, France
| | - Ali G Turhan
- INSERM UMR_S_1310, Université Paris Saclay, 94800 Villejuif, France
- Faculté de Médecine Paris Saclay, Université Paris Saclay, 94270 Le Kremlin-Bicêtre, France
- APHP Paris Saclay Service d'Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse, 94800 Villejuif, France
- APHP-Paris Saclay Service d'Hématologie-Bicêtre, 94270 Le Kremlin Bicêtre, France
- INGESTEM National iPSC Infrastructure, 94800 Villejuif, France
- Centre for iPSC Therapies (CITHERA) INSERM UMS 45, Génopole, 91100 Evry, France
| |
Collapse
|
8
|
Imeri J, Desterke C, Marcoux P, Chaker D, Oudrhiri N, Fund X, Faivre J, Bennaceur-Griscelli A, Turhan AG. Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance. Front Oncol 2023; 13:1117781. [PMID: 37007090 PMCID: PMC10062417 DOI: 10.3389/fonc.2023.1117781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 02/16/2023] [Indexed: 03/17/2023] Open
Abstract
The classical natural history of chronic myeloid leukemia (CML) has been drastically modified by the introduction of tyrosine kinase inhibitor (TKI) therapies. TKI discontinuation is currently possible in patients in deep molecular responses, using strict recommendations of molecular follow-up due to risk of molecular relapse, especially during the first 6 months. We report here the case of a patient who voluntarily interrupted her TKI therapy. She remained in deep molecular remission (MR4) for 18 months followed by detection of a molecular relapse at +20 months. Despite this relapse, she declined therapy until the occurrence of the hematological relapse (+ 4 years and 10 months). Retrospective sequential transcriptome experiments and a single-cell transcriptome RNA-seq analysis were performed. They revealed a molecular network focusing on several genes involved in both activation and inhibition of NK-T cell activity. Interestingly, the single-cell transcriptome analysis showed the presence of cells expressing NKG7, a gene involved in granule exocytosis and highly involved in anti-tumor immunity. Single cells expressing as granzyme H, cathepsin-W, and granulysin were also identified. The study of this case suggests that CML was controlled for a long period of time, potentially via an immune surveillance phenomenon. The role of NKG7 expression in the occurrence of treatment-free remissions (TFR) should be evaluated in future studies.
Collapse
Affiliation(s)
- Jusuf Imeri
- INSERM Unité Mixte de Recherche (UMR)_S_1310, Université Paris Saclay, Villejuif, France
| | - Christophe Desterke
- INSERM Unité Mixte de Recherche (UMR)_S_1310, Université Paris Saclay, Villejuif, France
- INGESTEM National IPSC Infrastructure, Villejuif, France
| | - Paul Marcoux
- INSERM Unité Mixte de Recherche (UMR)_S_1310, Université Paris Saclay, Villejuif, France
| | - Diana Chaker
- INSERM Unité Mixte de Recherche (UMR)_S_1310, Université Paris Saclay, Villejuif, France
- CITHERA, Center for iPSC Therapies, Evry, France
| | - Noufissa Oudrhiri
- INSERM Unité Mixte de Recherche (UMR)_S_1310, Université Paris Saclay, Villejuif, France
- INGESTEM National IPSC Infrastructure, Villejuif, France
- CITHERA, Center for iPSC Therapies, Evry, France
- APHP Paris Saclay, Division of Hematology, Paris Saclay University Hospitals, Le Kremlin Bicêtre, and Villejuif, France
| | - Xavier Fund
- INSERM Unité Mixte de Recherche (UMR)_S_1310, Université Paris Saclay, Villejuif, France
- APHP Paris Saclay, Division of Hematology, Paris Saclay University Hospitals, Le Kremlin Bicêtre, and Villejuif, France
| | - Jamila Faivre
- APHP Paris Saclay, Division of Hematology, Paris Saclay University Hospitals, Le Kremlin Bicêtre, and Villejuif, France
- Inserm Unité Mixte de Recherche (UMR) 1193 Centre-Hepato Biliaire, Paul Brousse, Villejuif, France
| | - Annelise Bennaceur-Griscelli
- INSERM Unité Mixte de Recherche (UMR)_S_1310, Université Paris Saclay, Villejuif, France
- INGESTEM National IPSC Infrastructure, Villejuif, France
- APHP Paris Saclay, Division of Hematology, Paris Saclay University Hospitals, Le Kremlin Bicêtre, and Villejuif, France
- Inserm Unité Mixte de Recherche (UMR) 1193 Centre-Hepato Biliaire, Paul Brousse, Villejuif, France
| | - Ali G. Turhan
- INSERM Unité Mixte de Recherche (UMR)_S_1310, Université Paris Saclay, Villejuif, France
- INGESTEM National IPSC Infrastructure, Villejuif, France
- APHP Paris Saclay, Division of Hematology, Paris Saclay University Hospitals, Le Kremlin Bicêtre, and Villejuif, France
- Inserm Unité Mixte de Recherche (UMR) 1193 Centre-Hepato Biliaire, Paul Brousse, Villejuif, France
- *Correspondence: Ali G. Turhan,
| |
Collapse
|
9
|
Rittavee Y, Artus J, Desterke C, Simanic I, de Souza LEB, Riccaldi S, Coignard S, Ijjeh Y, Hugues P, Bennaceur-Griscelli A, Turhan AG, Foudi A. miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells. Exp Hematol 2023; 118:40-52. [PMID: 36535407 DOI: 10.1016/j.exphem.2022.12.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 12/08/2022] [Accepted: 12/11/2022] [Indexed: 12/23/2022]
Abstract
Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy driven by the BCR-ABL1 fusion oncoprotein. The development of tyrosine kinase inhibitors (TKIs) has deeply increased long-term survival of CML patients. Nonetheless, one patient out of four will switch TKI off owing either to drug intolerance or resistance partly due to amplification or mutations of BCR-ABL1 oncogene and alteration in ATP-binding cassette (ABC) transporters. Increasing evidence suggests the involvement of the microRNA miR-495-3p in cancer-associated chemoresistance through multidrug resistance 1 (MDR1) gene, which encodes an ATP-dependent efflux pump. Our study aimed at investigating the potential role of miR-495-3p in CML TKI chemo-sensitivity and determining the underlying molecular circuitry involved. We first observed that miR-495-3p expression was lower in BCR-ABL1-expressing cellular models in vitro. Notably, loss-of-function experiments showed increased proliferation associated with a decreased number of nondividing cells (G0/G1) and resistance to Imatinib. Conversely, our data showed that miR-495-3p overexpression hindered leukemic cell growth and TKI resistance in Imatinib-resistant T315I-mutant cells, as well as drug efflux activity through MDR1 regulation. Further investigating the role of miR-495-3p in CML patients, we found that predicted miR-495-3p targets were upregulated in patients in blast crisis that were involved in protein phosphorylation and associated with the worst prognosis. Taken together, our results demonstrate that downregulation of miR-495-3p expression is important in the malignant phenotype of CML and TKI resistance mechanisms and could be a useful biomarker and a potential therapeutic target to eradicate CML.
Collapse
MESH Headings
- Humans
- Imatinib Mesylate/pharmacology
- Fusion Proteins, bcr-abl/genetics
- Fusion Proteins, bcr-abl/metabolism
- Tyrosine Protein Kinase Inhibitors
- Protein Kinase Inhibitors/pharmacology
- Protein Kinase Inhibitors/therapeutic use
- Cell Line, Tumor
- Drug Resistance, Neoplasm/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- MicroRNAs/genetics
- MicroRNAs/metabolism
- Drug Resistance, Multiple
- Adenosine Triphosphate
Collapse
Affiliation(s)
- Yutthana Rittavee
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France
| | - Jérôme Artus
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France
| | - Christophe Desterke
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France; INGESTEM National iPSC Infrastructure, Villejuif, France; INGESTEM National iPSC Infrastructure, Villejuif, France
| | - Isidora Simanic
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Lucas Eduardo Botelho de Souza
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Sandra Riccaldi
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Sabrina Coignard
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Yousef Ijjeh
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Patricia Hugues
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Annelise Bennaceur-Griscelli
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France; APHP Paris Saclay, Department of Hematology, Hôpital Bicêtre and Paul Brousse, Villejuif, France; INGESTEM National iPSC Infrastructure, Villejuif, France; CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Paris Saclay University, Genopole, Evry, France
| | - Ali G Turhan
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France; APHP Paris Saclay, Department of Hematology, Hôpital Bicêtre and Paul Brousse, Villejuif, France; INGESTEM National iPSC Infrastructure, Villejuif, France; CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Paris Saclay University, Genopole, Evry, France
| | - Adlen Foudi
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France.
| |
Collapse
|
10
|
M’Kacher R, Miguet M, Maillard PY, Colicchio B, Scheidecker S, Najar W, Arnoux M, Oudrhiri N, Borie C, Biehler M, Plesch A, Heidingsfelder L, Bennaceur-Griscelli A, Dieterlen A, Voisin P, Junker S, Carde P, Jeandidier E. A Central Role of Telomere Dysfunction in the Formation of a Unique Translocation within the Sub-Telomere Region Resulting in Duplication and Partial Trisomy. Genes (Basel) 2022; 13:genes13101762. [PMID: 36292646 PMCID: PMC9601474 DOI: 10.3390/genes13101762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Revised: 09/22/2022] [Accepted: 09/23/2022] [Indexed: 12/02/2022] Open
Abstract
Telomeres play a major role in maintaining genome stability and integrity. Putative involvement of telomere dysfunction in the formation of various types of chromosomal aberrations is an area of active research. Here, we report a case of a six-month-old boy with a chromosomal gain encompassing the 11q22.3q25 region identified by SNP array analysis. The size of the duplication is 26.7 Mb and contains 170 genes (OMIM). The duplication results in partial trisomy of the region in question with clinical consequences, including bilateral renal dysplasia, delayed development, and a heart defect. Moreover, the karyotype determined by R-banding and chromosome painting as well as by hybridization with specific sub-telomere probes revealed the presence of an unbalanced t(9;11)(p24;q22.3) translocation with a unique breakpoint involving the sub-telomere region of the short arm of chromosome 9. The karyotypes of the parents were normal. Telomere integrity in circulating lymphocytes from the child and from his parents was assessed using an automated high-throughput method based on fluorescence in situ hybridization (FISH) with telomere- and centromere-specific PNA probes followed by M-FISH multicolor karyotyping. Very short telomeres, as well as an increased frequency of telomere loss and formation of telomere doublets, were detected in the child’s cells. Interestingly, similar telomere profiles were found in the circulating lymphocytes of the father. Moreover, an assessment of clonal telomere aberrations identified chromosomes 9 and 11 with particularly high frequencies of such aberrations. These findings strongly suggest that telomere dysfunction plays a central role in the formation of this specific unbalanced chromosome rearrangement via chromosome end-to-end fusion and breakage–fusion–bridge cycles.
Collapse
Affiliation(s)
- Radhia M’Kacher
- Cell Environment DNA Damage R&D, Genopole, 91058 Evry, France
- Correspondence: (R.M.); (E.J.); Tel.: +33-1-60878918 (R.M.); +33-3-89648703 (E.J.)
| | - Marguerite Miguet
- Laboratoire de Génétique, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, 68070 Mulhouse, France
| | - Pierre-Yves Maillard
- Service de Génétique Hôpitaux Universitaires de Strasbourg, Hôpital de Haute Pierre, 1, Rue Molière, 67000 Strasbourg, France
| | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68070 Mulhouse, France
| | - Sophie Scheidecker
- Laboratoire de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, 1, Place de l’Hôpital, 67000 Strasbourg, France
| | - Wala Najar
- Cell Environment DNA Damage R&D, Genopole, 91058 Evry, France
| | - Micheline Arnoux
- APHP-Service d’Hématologie-Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay, 94801 Villejuif, France
| | - Noufissa Oudrhiri
- APHP-Service d’Hématologie-Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay, 94801 Villejuif, France
| | - Claire Borie
- APHP-Service d’Hématologie-Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay, 94801 Villejuif, France
| | - Margaux Biehler
- Laboratoire de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, 1, Place de l’Hôpital, 67000 Strasbourg, France
| | - Andreas Plesch
- MetaSystems GmbH, Robert-Bosch-Str. 6, 68804 Altlussheim, Germany
| | | | - Annelise Bennaceur-Griscelli
- APHP-Service d’Hématologie-Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay, 94801 Villejuif, France
| | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68070 Mulhouse, France
| | - Philippe Voisin
- Cell Environment DNA Damage R&D, Genopole, 91058 Evry, France
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, 8000 Aarhus, Denmark
| | - Patrice Carde
- Department of Hematology Gustave Roussy Cancer Campus, Paris Saclay, 94805 Villejuif, France
| | - Eric Jeandidier
- Laboratoire de Génétique, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, 68070 Mulhouse, France
- Correspondence: (R.M.); (E.J.); Tel.: +33-1-60878918 (R.M.); +33-3-89648703 (E.J.)
| |
Collapse
|
11
|
Kishi M, Asgarova A, Desterke C, Chaker D, Artus J, Turhan AG, Bennaceur-Griscelli A, Griscelli F. Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy. Front Med (Lausanne) 2021; 8:729018. [PMID: 34957134 PMCID: PMC8702815 DOI: 10.3389/fmed.2021.729018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Accepted: 11/18/2021] [Indexed: 12/27/2022] Open
Abstract
Cancer is maintained by the activity of a rare population of self-renewing "cancer stem cells" (CSCs), which are resistant to conventional therapies. CSCs over-express several proteins shared with induced pluripotent stem cells (iPSCs). We show here that allogenic or autologous murine iPSCs, combined with a histone deacetylase inhibitor (HDACi), are able to elicit major anti-tumor responses in a highly aggressive triple-negative breast cancer, as a relevant cancer stemness model. This immunotherapy strategy was effective in preventing tumor establishment and efficiently targeted CSCs by inducing extensive modifications of the tumor microenvironment. The anti-tumoral effect was correlated with the generation of CD4+, CD8+ T cells, and CD44+ CD62L- CCR7low CD127low T-effector memory cells, and the reduction of CD4+ CD25+FoxP3+ Tregs, Arg1+ CD11b+ Gr1+, and Arg1+ and CD11b+ Ly6+ myeloid-derived suppressor cell populations within the tumor. The anti-tumoral effect was associated with a reduction in metastatic dissemination and an improvement in the survival rate. These results demonstrate for the first time the clinical relevance of using an off-the-shelf allogeneic iPSC-based vaccine combined with an HDACi as a novel pan-cancer anti-cancer immunotherapy strategy against aggressive tumors harboring stemness features with high metastatic potential.
Collapse
Affiliation(s)
- Masae Kishi
- Institut National de la Santé et de la Recherche Médicale (INSERM) UA9-Human Pluripotent Stem Cell Core Facility, CITHERA Infrastructure-INGESTEM, Villejuif, France
| | - Afag Asgarova
- Institut National de la Santé et de la Recherche Médicale (INSERM) UA9-Human Pluripotent Stem Cell Core Facility, CITHERA Infrastructure-INGESTEM, Villejuif, France
| | - Christophe Desterke
- Institut National de la Santé et de la Recherche Médicale (INSERM) UA9-Human Pluripotent Stem Cell Core Facility, CITHERA Infrastructure-INGESTEM, Villejuif, France.,Université Paris-Saclay, Faculté de Médecine, Kremlin Bicêtre, France
| | - Diana Chaker
- Institut National de la Santé et de la Recherche Médicale (INSERM) UA9-Human Pluripotent Stem Cell Core Facility, CITHERA Infrastructure-INGESTEM, Villejuif, France
| | - Jérôme Artus
- Institut National de la Santé et de la Recherche Médicale (INSERM) UA9-Human Pluripotent Stem Cell Core Facility, CITHERA Infrastructure-INGESTEM, Villejuif, France.,Université Paris-Saclay, Faculté de Médecine, Kremlin Bicêtre, France
| | - Ali G Turhan
- Institut National de la Santé et de la Recherche Médicale (INSERM) UA9-Human Pluripotent Stem Cell Core Facility, CITHERA Infrastructure-INGESTEM, Villejuif, France.,Université Paris-Saclay, Faculté de Médecine, Kremlin Bicêtre, France.,APHP Paris-Saclay Service d'Hématologie, Hôpital Universitaire Paris Sud (AP-HP), Kremlin Bicêtre, France
| | - Annelise Bennaceur-Griscelli
- Institut National de la Santé et de la Recherche Médicale (INSERM) UA9-Human Pluripotent Stem Cell Core Facility, CITHERA Infrastructure-INGESTEM, Villejuif, France.,Université Paris-Saclay, Faculté de Médecine, Kremlin Bicêtre, France.,APHP Paris-Saclay Service d'Hématologie, Hôpital Universitaire Paris Sud (AP-HP), Kremlin Bicêtre, France
| | - Frank Griscelli
- Institut National de la Santé et de la Recherche Médicale (INSERM) UA9-Human Pluripotent Stem Cell Core Facility, CITHERA Infrastructure-INGESTEM, Villejuif, France.,Université Paris Descartes, Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France.,Département de Biologie Médicale et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France
| |
Collapse
|
12
|
Soumboundou M, Dossou J, Kalaga Y, Nkengurutse I, Faye I, Guingani A, Gadji M, Yameogo KJ, Zongo H, Mbaye G, Dem A, Diarra M, Adjibade R, Djebou C, Junker S, Oudrhiri N, Hempel WM, Dieterlen A, Jeandidier E, Carde P, El Maalouf E, Colicchio B, Bennaceur-Griscelli A, Fenech M, Voisin P, Rodriguez-Lafrasse C, M'Kacher R. Is Response to Genotoxic Stress Similar in Populations of African and European Ancestry? A Study of Dose-Response After in vitro Irradiation. Front Genet 2021; 12:657999. [PMID: 34868192 PMCID: PMC8632650 DOI: 10.3389/fgene.2021.657999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2021] [Accepted: 05/13/2021] [Indexed: 11/17/2022] Open
Abstract
Background: Exposure to genotoxic stress such as radiation is an important public health issue affecting a large population. The necessity of analyzing cytogenetic effects of such exposure is related to the need to estimate the associated risk. Cytogenetic biological dosimetry is based on the relationship between the absorbed dose and the frequency of scored chromosomal aberrations. The influence of confounding factors on radiation response is a topical issue. The role of ethnicity is unclear. Here, we compared the dose-response curves obtained after irradiation of circulating lymphocytes from healthy donors of African and European ancestry. Materials and Methods: Blood samples from six Africans living in Africa, five Africans living in Europe, and five Caucasians living in Europe were exposed to various doses (0–4 Gy) of X-rays at a dose-rate of 0.1 Gy/min using an X-RAD320 irradiator. A validated cohort composed of 14 healthy Africans living in three African countries was included and blood samples were irradiated using the same protocols. Blood lymphocytes were cultured for 48 h and chromosomal aberrations scored during the first mitosis by telomere and centromere staining. The distribution of dicentric chromosomes was determined and the Kruskal-Wallis test was used to compare the dose-response curves of the two populations. Results: No spontaneous dicentric chromosomes were detected in African donors, thus establishing a very low background of unstable chromosomal aberrations relative to the European population. There was a significant difference in the dose response curves between native African and European donors. At 4 Gy, African donors showed a significantly lower frequency of dicentric chromosomes (p = 8.65 10–17), centric rings (p = 4.0310–14), and resulting double-strand-breaks (DSB) (p = 1.32 10–18) than European donors. In addition, a significant difference was found between African donors living in Europe and Africans living in Africa. Conclusion: This is the first study to demonstrate the important role of ethnic and environmental factors that may epigenetically influence the response to irradiation. It will be necessary to establish country-of-origen-specific dose response curves to practice precise and adequate biological dosimetry. This work opens new perspective for the comparison of treatments based on genotoxic agents, such as irradiation.
Collapse
Affiliation(s)
| | - Julien Dossou
- Département du Génie d'Imagerie Médicale et Radiobiologie, Cotonou, Benin
| | - Yossef Kalaga
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | | | | | - Albert Guingani
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | | | - Koudbi J Yameogo
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | - Henri Zongo
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | - Gora Mbaye
- Laboratoire Biophysique UFR-Santé, Dakar, Senegal
| | | | | | - Rached Adjibade
- Département du Génie d'Imagerie Médicale et Radiobiologie, Cotonou, Benin
| | - Catherine Djebou
- Département du Génie d'Imagerie Médicale et Radiobiologie, Cotonou, Benin
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, Aarhus, Denmark
| | - Noufissa Oudrhiri
- APHP-Service d'Hématologie - Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/Inserm UMR 935, Villejuif, France
| | | | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, Mulhouse, France
| | - Eric Jeandidier
- Service de Génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, France
| | - Patrice Carde
- Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, France
| | | | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, Mulhouse, France
| | - Annelise Bennaceur-Griscelli
- APHP-Service d'Hématologie - Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/Inserm UMR 935, Villejuif, France
| | - Michael Fenech
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia.,Genome Health Foundation, North Brighton, SA, Australia.,Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | | | - Claire Rodriguez-Lafrasse
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, UMR CNRS5822/IN2P3, IPNL, PRISME, Oullins, France
| | | |
Collapse
|
13
|
Turhan AG, Hwang JW, Chaker D, Tasteyre A, Latsis T, Griscelli F, Desterke C, Bennaceur-Griscelli A. iPSC-Derived Organoids as Therapeutic Models in Regenerative Medicine and Oncology. Front Med (Lausanne) 2021; 8:728543. [PMID: 34722569 PMCID: PMC8548367 DOI: 10.3389/fmed.2021.728543] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Accepted: 09/17/2021] [Indexed: 01/22/2023] Open
Abstract
Progress made during the last decade in stem cell biology allows currently an unprecedented potential to translate these advances into the clinical applications and to shape the future of regenerative medicine. Organoid technology is amongst these major developments, derived from primary tissues or more recently, from induced pluripotent stem cells (iPSC). The use of iPSC technology offers the possibility of cancer modeling especially in hereditary cancers with germline oncogenic mutations. Similarly, it has the advantage to be amenable to genome editing with introduction of specific oncogenic alterations using CRISPR-mediated gene editing. In the field of regenerative medicine, iPSC-derived organoids hold promise for the generation of future advanced therapeutic medicinal products (ATMP) for organ repair. Finally, it appears that they can be of highly useful experimental tools to determine cell targets of SARS-Cov-2 infections allowing to test anti-Covid drugs. Thus, with the possibilities of genomic editing and the development of new protocols for differentiation toward functional tissues, it is expected that iPSC-derived organoid technology will represent also a therapeutic tool in all areas of medicine.
Collapse
Affiliation(s)
- Ali G Turhan
- INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France.,ESTeam Paris Sud, Université Paris Saclay, Villejuif, France.,APHP Paris Saclay, Department of Hematology, Hopital Bicetre and Paul Brousse, Villejuif, France.,INGESTEM National iPSC Infrastructure, Villejuif, France.,CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Genopole, Evry, France
| | - Jinwook W Hwang
- INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France.,ESTeam Paris Sud, Université Paris Saclay, Villejuif, France
| | - Diana Chaker
- INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France.,ESTeam Paris Sud, Université Paris Saclay, Villejuif, France.,INGESTEM National iPSC Infrastructure, Villejuif, France.,CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Genopole, Evry, France
| | - Albert Tasteyre
- INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France.,ESTeam Paris Sud, Université Paris Saclay, Villejuif, France.,INGESTEM National iPSC Infrastructure, Villejuif, France.,CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Genopole, Evry, France
| | - Theodoros Latsis
- INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France.,ESTeam Paris Sud, Université Paris Saclay, Villejuif, France.,INGESTEM National iPSC Infrastructure, Villejuif, France
| | - Frank Griscelli
- INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France.,ESTeam Paris Sud, Université Paris Saclay, Villejuif, France.,INGESTEM National iPSC Infrastructure, Villejuif, France.,CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Genopole, Evry, France.,Université Paris Descartes, Faculté Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France
| | - Christophe Desterke
- INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France.,ESTeam Paris Sud, Université Paris Saclay, Villejuif, France.,INGESTEM National iPSC Infrastructure, Villejuif, France
| | - Annelise Bennaceur-Griscelli
- INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France.,ESTeam Paris Sud, Université Paris Saclay, Villejuif, France.,APHP Paris Saclay, Department of Hematology, Hopital Bicetre and Paul Brousse, Villejuif, France.,INGESTEM National iPSC Infrastructure, Villejuif, France.,CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Genopole, Evry, France
| |
Collapse
|
14
|
Desterke C, Bennaceur-Griscelli A, Turhan AG. EGR1 dysregulation defines an inflammatory and leukemic program in cell trajectory of human-aged hematopoietic stem cells (HSC). Stem Cell Res Ther 2021; 12:419. [PMID: 34294125 PMCID: PMC8296523 DOI: 10.1186/s13287-021-02498-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Accepted: 07/08/2021] [Indexed: 12/24/2022] Open
Abstract
Background During aging, hematopoietic stem cells (HSC) lose progressively both their self-renewal and differentiation potential. The precise molecular mechanisms of this phenomenon are not well established. To uncover the molecular events underlying this event, we have performed a bioinformatics analysis of 650 single-cell transcriptomes. Methods Single-cell transcriptome analyses of expression heterogeneity, cell cycle, and cell trajectory in human cell compartment enriched in hematopoietic stem cell compartment were investigated in the bone marrow according to the age of the donors. Identification of aging-related nodules was identified by weighted correlation network analysis in this primitive compartment. Results The analysis of single-cell transcriptomes allowed to uncover a major upregulation of EGR1 in human-aged lineage−CD34+CD38− cells which present cell cycle dysregulation with reduction of G2/M phase according to less expression of CCND2 during S phase. EGR1 upregulation in aging hematopoietic stem cells was found to be independent of cell cycle phases and gender. EGR1 expression trajectory in aged HSC highlighted a signature enriched in hematopoietic and immune disorders with the best induction of AP-1 complex and quiescence regulators such as EGR1, BTG2, JUNB, and NR41A. Sonic Hedgehog-related TMEM107 transmembrane molecule followed also EGR1 cell trajectory. EGR1-dependent gene weighted network analysis in human HSC-associated IER2 target protein-specific regulators of PP2A activity, IL1B, TNFSF10 ligands, and CD69, SELP membrane molecules in old HSC module with immune and leukemogenic signature. In contrast, for young HSC which were found with different cell cycle phase progression, its specific module highlighted upregulation of HIF1A hypoxic factor, PDE4B immune marker, DRAK2 (STK17B) T cell apoptosis regulator, and MYADM myeloid-associated marker. Conclusion EGR1 was found to be connected to the aging of human HSC and highlighted a specific cell trajectory contributing to the dysregulation of an inflammatory and leukemia-related transcriptional program in aged human HSCs. EGR1 and its program were found to be connected to the aging of human HSC with dissociation of quiescence property and cell cycle phase progression in this primitive hematopoietic compartment. Supplementary Information The online version contains supplementary material available at 10.1186/s13287-021-02498-0.
Collapse
Affiliation(s)
| | - Annelise Bennaceur-Griscelli
- INSERM UA9, University Paris-Saclay, 94800, Villejuif, France.,ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, University Paris-Saclay, 94800, Villejuif, France.,Division of Hematology, APHP-Paris Saclay University Hospitals, Le Kremlin Bicêtre 94275, 94800, Villejuif, France.,Faculty of Medicine, University Paris Saclay, 94275, Le Kremlin Bicêtre, France
| | - Ali G Turhan
- INSERM UA9, University Paris-Saclay, 94800, Villejuif, France. .,ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, University Paris-Saclay, 94800, Villejuif, France. .,Division of Hematology, APHP-Paris Saclay University Hospitals, Le Kremlin Bicêtre 94275, 94800, Villejuif, France. .,Faculty of Medicine, University Paris Saclay, 94275, Le Kremlin Bicêtre, France.
| |
Collapse
|
15
|
Desterke C, Turhan AG, Bennaceur-Griscelli A, Griscelli F. HLA-dependent heterogeneity and macrophage immunoproteasome activation during lung COVID-19 disease. J Transl Med 2021; 19:290. [PMID: 34225749 PMCID: PMC8256232 DOI: 10.1186/s12967-021-02965-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 06/27/2021] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The worldwide pandemic caused by the SARS-CoV-2 virus is characterized by significant and unpredictable heterogeneity in symptoms that remains poorly understood. METHODS Transcriptome and single cell transcriptome of COVID19 lung were integrated with deeplearning analysis of MHC class I immunopeptidome against SARS-COV2 proteome. RESULTS An analysis of the transcriptomes of lung samples from COVID-19 patients revealed that activation of MHC class I antigen presentation in these tissues was correlated with the amount of SARS-CoV-2 RNA present. Similarly, a positive relationship was detected in these samples between the level of SARS-CoV-2 and the expression of a genomic cluster located in the 6p21.32 region (40 kb long, inside the MHC-II cluster) that encodes constituents of the immunoproteasome. An analysis of single-cell transcriptomes of bronchoalveolar cells highlighted the activation of the immunoproteasome in CD68 + M1 macrophages of COVID-19 patients in addition to a PSMB8-based trajectory in these cells that featured an activation of defense response during mild cases of the disease, and an impairment of alveolar clearance mechanisms during severe COVID-19. By examining the binding affinity of the SARS-CoV-2 immunopeptidome with the most common HLA-A, -B, and -C alleles worldwide, we found higher numbers of stronger presenters in type A alleles and in Asian populations, which could shed light on why this disease is now less widespread in this part of the world. CONCLUSIONS HLA-dependent heterogeneity in macrophage immunoproteasome activation during lung COVID-19 disease could have implications for efforts to predict the response to HLA-dependent SARS-CoV-2 vaccines in the global population.
Collapse
Affiliation(s)
- Christophe Desterke
- INSERM UA9- University Paris-Saclay, 94800, Villejuif, France
- University Paris Saclay, Faculty of Medicine, 94275, Le Kremlin Bicêtre, France
| | - Ali G Turhan
- INSERM UA9- University Paris-Saclay, 94800, Villejuif, France
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, University Paris-Saclay, 94800, Villejuif, France
- Division of Hematology, Kremlin-Bicetre Hospital, 94270, Kremlin Bicetre, France
- University Paris Saclay, Faculty of Medicine, 94275, Le Kremlin Bicêtre, France
| | - Annelise Bennaceur-Griscelli
- INSERM UA9- University Paris-Saclay, 94800, Villejuif, France
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, University Paris-Saclay, 94800, Villejuif, France
- Division of Hematology, Kremlin-Bicetre Hospital, 94270, Kremlin Bicetre, France
- University Paris Saclay, Faculty of Medicine, 94275, Le Kremlin Bicêtre, France
| | - Frank Griscelli
- INSERM UA9- University Paris-Saclay, 94800, Villejuif, France.
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, University Paris-Saclay, 94800, Villejuif, France.
- University of Paris, Faculty Sorbonne Paris Cité, Faculté Des Sciences Pharmaceutiques Et Biologiques, Paris, France.
- Department of Biopathology, Gustave-Roussy Cancer Institute, 94800, Villejuif, France.
- INSERM UA9, Institut André Lwoff, Hôpital Paul Brousse, Bâtiment A CNRS, 7 rue Guy Moquet, 94802, Villejuif, France.
| |
Collapse
|
16
|
Hwang JW, Desterke C, Loisel-Duwattez J, Griscelli F, Bennaceur-Griscelli A, Turhan AG. Detection of Hematopoietic Stem Cell Transcriptome in Human Fetal Kidneys and Kidney Organoids Derived From Human Induced Pluripotent Stem Cells. Front Cell Dev Biol 2021; 9:668833. [PMID: 34178994 PMCID: PMC8226023 DOI: 10.3389/fcell.2021.668833] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Accepted: 05/12/2021] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND In mammalians, hematopoietic stem cells (HSCs) arise in the dorsal aorta from the hemogenic endothelium, followed by their migration to the fetal liver and to the bone marrow. In zebrafish, the kidney is the site of primary hematopoiesis. In humans, the presence of HSCs in the fetal or adult kidney has not been established. METHODS We analyzed the presence of HSC markers in the human fetal kidneys by analysis of single-cell datasets. We then analyzed in kidney organoids derived from induced pluripotent stem cells (iPSCs) the presence of hematopoietic markers using transcriptome analyses. RESULTS Twelve clusters were identified as stromal, endothelial, and nephron cell type-specific markers in the two fetal stage (17 weeks) kidney datasets. Among these, the expression of hematopoietic cells in cluster 9 showed an expression of primitive markers. Moreover, whole transcriptome analysis of our iPSC-derived kidney organoids revealed induction of the primitive hematopoietic transcription factor RUNX1 as found in the human fetal kidney cortex. CONCLUSION These finding support the presence of cells expressing HSC transcriptome in the human kidney. The mechanisms of the appearance of the cells with the same transcriptional features during iPSC-derived kidney organoid generation require further investigation.
Collapse
Affiliation(s)
- Jin Wook Hwang
- INSERM U935/UA09, Université Paris-Saclay, Villejuif, France
- ESTeam Paris Sud, Université Paris Sud, Villejuif, France
| | - Christophe Desterke
- INSERM U935/UA09, Université Paris-Saclay, Villejuif, France
- ESTeam Paris Sud, Université Paris Sud, Villejuif, France
| | - Julien Loisel-Duwattez
- INSERM U1195, AP-HP, Service de Neurologie, Faculté de Médecine, Hôpital Bicêtre, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Frank Griscelli
- INSERM U935/UA09, Université Paris-Saclay, Villejuif, France
- ESTeam Paris Sud, Université Paris Sud, Villejuif, France
- INGESTEM National IPSC Infrastructure, Villejuif, France
- Division of Hematology, AP-HP Paris Saclay, Le Kremlin-Bicêtre, France
| | - Annelise Bennaceur-Griscelli
- INSERM U935/UA09, Université Paris-Saclay, Villejuif, France
- ESTeam Paris Sud, Université Paris Sud, Villejuif, France
- INGESTEM National IPSC Infrastructure, Villejuif, France
- Division of Hematology, AP-HP Paris Saclay, Le Kremlin-Bicêtre, France
| | - Ali G. Turhan
- INSERM U935/UA09, Université Paris-Saclay, Villejuif, France
- ESTeam Paris Sud, Université Paris Sud, Villejuif, France
- INGESTEM National IPSC Infrastructure, Villejuif, France
- Division of Hematology, AP-HP Paris Saclay, Le Kremlin-Bicêtre, France
| |
Collapse
|
17
|
Portier L, Desterke C, Chaker D, Oudrhiri N, Asgarova A, Dkhissi F, Turhan AG, Bennaceur-Griscelli A, Griscelli F. iPSC-Derived Hereditary Breast Cancer Model Reveals the BRCA1-Deleted Tumor Niche as a New Culprit in Disease Progression. Int J Mol Sci 2021; 22:ijms22031227. [PMID: 33513753 PMCID: PMC7866119 DOI: 10.3390/ijms22031227] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Revised: 01/22/2021] [Accepted: 01/23/2021] [Indexed: 01/05/2023] Open
Abstract
Tumor progression begins when cancer cells recruit tumor-associated stromal cells to produce a vascular niche, ultimately resulting in uncontrolled growth, invasion, and metastasis. It is poorly understood, though, how this process might be affected by deletions or mutations in the breast cancer type 1 susceptibility (BRCA1) gene in patients with a lifetime risk of developing breast and/or ovarian cancer. To model the BRCA1-deleted stroma, we first generated induced pluripotent stem cells (iPSCs) from patients carrying a germline deletion of exon 17 of the BRCA1 gene (BRCA1+/− who, based on their family histories, were at a high risk for cancer. Using peripheral blood mononuclear cells (PBMCs) of these two affected family members and two normal (BRCA1+/+) individuals, we established a number of iPSC clones via non-integrating Sendai virus-based delivery of the four OCT4, SOX2, KLF4, and c-MYC factors. Induced mesenchymal stem cells (iMSCs) were generated and used as normal and pathological stromal cells. In transcriptome analyses, BRCA1+/− iMSCs exhibited a unique pro-angiogenic signature: compared to non-mutated iMSCs, they expressed high levels of HIF-1α, angiogenic factors belonging to the VEGF, PDGF, and ANGPT subfamilies showing high angiogenic potential. This was confirmed in vitro through the increased capacity to generate tube-like structures compared to BRCA1+/+ iMSCs and in vivo by a matrigel plug angiogenesis assay where the BRCA1+/− iMSCs promoted the development of an extended and organized vessel network. We also reported a highly increased migration capacity of BRCA1+/− iMSCs through an in vitro wound healing assay that correlated with the upregulation of the periostin (POSTN). Finally, we assessed the ability of both iMSCs to facilitate the engraftment of murine breast cancer cells using a xenogenic 4T1 transplant model. The co-injection of BRCA1+/− iMSCs and 4T1 breast cancer cells into mouse mammary fat pads gave rise to highly aggressive tumor growth (2-fold increase in tumor volume compared to 4T1 alone, p = 0.01283) and a higher prevalence of spontaneous metastatic spread to the lungs. Here, we report for the first time a major effect of BRCA1 haploinsufficiency on tumor-associated stroma in the context of BRCA1-associated cancers. The unique iMSC model used here was generated using patient-specific iPSCs, which opens new therapeutic avenues for the prevention and personalized treatment of BRCA1-associated hereditary breast cancer.
Collapse
Affiliation(s)
- Lucie Portier
- Institut National de la Santé et de la Recherche Médicale–UMR935/UA9, University Paris-Saclay, 94800 Villejuif, France; (L.P.); (C.D.); (D.C.); (N.O.); (A.A.); (A.G.T.); (A.B.-G.)
| | - Christophe Desterke
- Institut National de la Santé et de la Recherche Médicale–UMR935/UA9, University Paris-Saclay, 94800 Villejuif, France; (L.P.); (C.D.); (D.C.); (N.O.); (A.A.); (A.G.T.); (A.B.-G.)
- INGESTEM, CITHERA, National IPSC Infrastructure, INSERM University Paris-Saclay, 94800 Villejuif, France
| | - Diana Chaker
- Institut National de la Santé et de la Recherche Médicale–UMR935/UA9, University Paris-Saclay, 94800 Villejuif, France; (L.P.); (C.D.); (D.C.); (N.O.); (A.A.); (A.G.T.); (A.B.-G.)
- INGESTEM, CITHERA, National IPSC Infrastructure, INSERM University Paris-Saclay, 94800 Villejuif, France
| | - Noufissa Oudrhiri
- Institut National de la Santé et de la Recherche Médicale–UMR935/UA9, University Paris-Saclay, 94800 Villejuif, France; (L.P.); (C.D.); (D.C.); (N.O.); (A.A.); (A.G.T.); (A.B.-G.)
- INGESTEM, CITHERA, National IPSC Infrastructure, INSERM University Paris-Saclay, 94800 Villejuif, France
- Division of Hematology, APHP-Paris Sud University Hospitals, 94270 Le Kremlin Bicêtre, France
| | - Afag Asgarova
- Institut National de la Santé et de la Recherche Médicale–UMR935/UA9, University Paris-Saclay, 94800 Villejuif, France; (L.P.); (C.D.); (D.C.); (N.O.); (A.A.); (A.G.T.); (A.B.-G.)
- INGESTEM, CITHERA, National IPSC Infrastructure, INSERM University Paris-Saclay, 94800 Villejuif, France
| | - Fatima Dkhissi
- Institut National de la Santé et de la Recherche Médicale, UMR1082, University of Poitiers, 86000 Poitiers, France;
| | - Ali G. Turhan
- Institut National de la Santé et de la Recherche Médicale–UMR935/UA9, University Paris-Saclay, 94800 Villejuif, France; (L.P.); (C.D.); (D.C.); (N.O.); (A.A.); (A.G.T.); (A.B.-G.)
- INGESTEM, CITHERA, National IPSC Infrastructure, INSERM University Paris-Saclay, 94800 Villejuif, France
- Division of Hematology, APHP-Paris Sud University Hospitals, 94270 Le Kremlin Bicêtre, France
- Faculty of Medecine, University Paris-Saclay, 94270 Le Kremlin Bicêtre, France
| | - Annelise Bennaceur-Griscelli
- Institut National de la Santé et de la Recherche Médicale–UMR935/UA9, University Paris-Saclay, 94800 Villejuif, France; (L.P.); (C.D.); (D.C.); (N.O.); (A.A.); (A.G.T.); (A.B.-G.)
- INGESTEM, CITHERA, National IPSC Infrastructure, INSERM University Paris-Saclay, 94800 Villejuif, France
- Division of Hematology, APHP-Paris Sud University Hospitals, 94270 Le Kremlin Bicêtre, France
- Faculty of Medecine, University Paris-Saclay, 94270 Le Kremlin Bicêtre, France
| | - Frank Griscelli
- Institut National de la Santé et de la Recherche Médicale–UMR935/UA9, University Paris-Saclay, 94800 Villejuif, France; (L.P.); (C.D.); (D.C.); (N.O.); (A.A.); (A.G.T.); (A.B.-G.)
- INGESTEM, CITHERA, National IPSC Infrastructure, INSERM University Paris-Saclay, 94800 Villejuif, France
- Département de Biologie Médicale et Pathologie Médicales, Service de microbiologie, Gustave Roussy Cancer Campus, 94805 Villejuif, France
- Faculté de la Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, University of Paris, 75006 Paris, France
- Correspondence: ; Tel.: +33-1-4211-5193; Fax: 33-1-4559-3718
| |
Collapse
|
18
|
M'kacher R, Colicchio B, Marquet V, Borie C, Najar W, Hempel WM, Heidingsfelder L, Oudrhiri N, Al Jawhari M, Wilhelm-Murer N, Miguet M, Dieterlen A, Deschênes G, Tabet AC, Junker S, Grynberg M, Fenech M, Bennaceur-Griscelli A, Voisin P, Carde P, Jeandidier E, Yardin C. Telomere aberrations, including telomere loss, doublets, and extreme shortening, are increased in patients with infertility. Fertil Steril 2020; 115:164-173. [PMID: 33272625 DOI: 10.1016/j.fertnstert.2020.07.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Revised: 07/02/2020] [Accepted: 07/06/2020] [Indexed: 01/07/2023]
Abstract
OBJECTIVE To test the hypothesis that telomere shortening and/or loss are risk factors for infertility. DESIGN Retrospective analysis of the telomere status in patients with infertility using conventional cytogenetic data collected prospectively. SETTING Academic centers. PATIENT(S) Cytogenetic slides with cultured peripheral lymphocytes from 50 patients undergoing fertility treatment and 150 healthy donors, including 100 donors matched for age. INTERVENTION(S) Cytogenetic slides were used to detect chromosomal and telomere aberrations. MAIN OUTCOME MEASURE(S) Telomere length and telomere aberrations were analyzed after telomere and centromere staining. RESULT(S) The mean telomere length of patients consulting for infertility was significantly less than that of healthy donors of similar age. Moreover, patients with infertility showed significantly more extreme telomere loss and telomere doublet formation than healthy controls. Telomere shortening and/or telomere aberrations were more pronounced in patients with structural chromosomal aberrations. Dicentric chromosomes were identified in 6/13 patients, with constitutional chromosomal aberrations leading to chromosomal instability that correlated with chromosomal end-to-end fusions. CONCLUSION(S) Our findings demonstrate the feasibility of analyzing telomere aberrations in addition to chromosomal aberrations, using cytogenetic slides. Telomere attrition and/or dysfunction represent the main common cytogenetic characteristic of patients with infertility, leading to potential implications for fertility assessment. Pending further studies, these techniques that correlate the outcome of assisted reproduction and telomere integrity status may represent a novel and useful diagnostic and/or prognostic tool for medical care in this field.
Collapse
Affiliation(s)
- Radhia M'kacher
- Cell Environment, DNA Damage Research & Development, Paris, France.
| | - Bruno Colicchio
- Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, Mulhouse, France
| | - Valentine Marquet
- Service de Cytogénétique, Génétique Médicale, et Biologie de la Reproduction Hôpital de la Mère et de l'Enfant, Centre hospitalo-universitaire Dupuytren, Limoges, France
| | - Claire Borie
- Assitance Pubique-Hopitaux de Paris (APHP)-Service d'hématologie-Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/INSERM 935, Villejuif, France
| | - Wala Najar
- Cell Environment, DNA Damage Research & Development, Paris, France; Faculté de médecine Paris Centre, Université de Paris, Paris, France
| | - William M Hempel
- Cell Environment, DNA Damage Research & Development, Paris, France
| | | | - Noufissa Oudrhiri
- Assitance Pubique-Hopitaux de Paris (APHP)-Service d'hématologie-Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/INSERM 935, Villejuif, France
| | | | - Nadège Wilhelm-Murer
- Service de génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, France
| | - Marguerite Miguet
- Service de génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, France
| | - Alain Dieterlen
- Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, Mulhouse, France
| | | | | | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, Aarhus, Denmark
| | - Michael Grynberg
- Department of Reproductive Medicine and Fertility Preservation, Hôpital Antoine Béclère, Clamart, France
| | - Michael Fenech
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia; Genome Health Foundation, North Brighton, South Australia, Australia
| | - Annelise Bennaceur-Griscelli
- Assitance Pubique-Hopitaux de Paris (APHP)-Service d'hématologie-Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/INSERM 935, Villejuif, France
| | - Philippe Voisin
- Cell Environment, DNA Damage Research & Development, Paris, France
| | - Patrice Carde
- Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, France
| | - Eric Jeandidier
- Service de génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, France
| | - Catherine Yardin
- Service de Cytogénétique, Génétique Médicale, et Biologie de la Reproduction Hôpital de la Mère et de l'Enfant, Centre hospitalo-universitaire Dupuytren, Limoges, France; CNRS, XLIM, UMR 7252, University of Limoges, Limoges, France
| |
Collapse
|
19
|
Desterke C, Griscelli F, Imeri J, Marcoux P, Lemonnier T, Latsis T, Turhan AG, Bennaceur-Griscelli A. Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID-19-associated organ failure. Stem Cells Transl Med 2020; 10:568-571. [PMID: 33237619 PMCID: PMC7753753 DOI: 10.1002/sctm.20-0189] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Revised: 09/18/2020] [Accepted: 09/26/2020] [Indexed: 12/16/2022] Open
Abstract
The use of mesenchymal stem cells (MSC) derived from several sources has been suggested as a major anti-inflammation strategy during the recent outbreak of coronavirus-19 (COVID-19). As the virus enters the target cells through the receptor ACE2, it is important to determine if the MSC population transfused to patients could also be a target for the virus entry. We report here that ACE2 is highly expressed in adult bone marrow, adipose tissue, or umbilical cord-derived MSC. On the other hand, placenta-derived MSC express low levels of ACE2 but only in early passages of cultures. MSC derived from human embryonic stem cell or human induced pluripotent stem cells express also very low levels of ACE2. The transcriptome analysis of the MSCs with lowest expression of ACE2 in fetal-like MSCs is found to be associated in particularly with an anti-inflammatory signature. These results are of major interest for designing future clinical MSC-based stem cell therapies for severe COVID-19 infections.
Collapse
Affiliation(s)
- Christophe Desterke
- INSERM UMR-S 935 and University Paris Saclay, Villejuif, France.,INGESTEM National IPSC Infrastructure, Villejuif, France
| | - Frank Griscelli
- INSERM UMR-S 935 and University Paris Saclay, Villejuif, France.,INGESTEM National IPSC Infrastructure, Villejuif, France.,Gustave Roussy Institute, Villejuif and Faculty of Pharmacy, Paris Descartes University, Paris, France
| | - Jusuf Imeri
- INSERM UMR-S 935 and University Paris Saclay, Villejuif, France
| | - Paul Marcoux
- INSERM UMR-S 935 and University Paris Saclay, Villejuif, France
| | | | - Theodoros Latsis
- INSERM UMR-S 935 and University Paris Saclay, Villejuif, France.,INGESTEM National IPSC Infrastructure, Villejuif, France
| | - Ali G Turhan
- INSERM UMR-S 935 and University Paris Saclay, Villejuif, France.,INGESTEM National IPSC Infrastructure, Villejuif, France.,APHP Paris Saclay Division of Hematology and University Paris Saclay Faculty of Medicine, Villejuif, France
| | - Annelise Bennaceur-Griscelli
- INSERM UMR-S 935 and University Paris Saclay, Villejuif, France.,INGESTEM National IPSC Infrastructure, Villejuif, France.,APHP Paris Saclay Division of Hematology and University Paris Saclay Faculty of Medicine, Villejuif, France
| |
Collapse
|
20
|
Desterke C, Turhan AG, Bennaceur-Griscelli A, Griscelli F. PPARγ Cistrome Repression during Activation of Lung Monocyte-Macrophages in Severe COVID-19. iScience 2020; 23:101611. [PMID: 33015591 PMCID: PMC7518203 DOI: 10.1016/j.isci.2020.101611] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 08/06/2020] [Accepted: 09/22/2020] [Indexed: 12/19/2022] Open
Abstract
The molecular mechanisms of cytokine storm in patients with severe COVID-19 infections are poorly understood. To uncover these events, we performed transcriptome analyses of lung biopsies from patients with COVID-19, revealing a gene enrichment pattern similar to that of PPARγ-knockout macrophages. Single-cell gene expression analysis of bronchoalveolar lavage fluids revealed a characteristic trajectory of PPARγ-related disturbance in the CD14+/CD16+ cells. We identified a correlation with the disease severity and the reduced expression of several members of the PPARγ complex such as EP300, RXRA, RARA, SUMO1, NR3C1, and CCDC88A. ChIP-seq analyses confirmed repression of the PPARγ-RXRA-NR3C1 cistrome in COVID-19 lung samples. Further analysis of protein-protein networks highlighted an interaction between the PPARγ-associated protein SUMO1 and a nucleoprotein of the SARS virus. Overall, these results demonstrate for the first time the involvement of the PPARγ complex in severe COVID-19 lung disease and suggest strongly its role in the major monocyte/macrophage-mediated inflammatory storm.
Collapse
Affiliation(s)
- Christophe Desterke
- INSERM UA9- University Paris-Saclay, Institut André Lwoff, Bâtiment A CNRS, 7 rue Guy Moquet, 94800 Villejuif, France
| | - Ali G Turhan
- INSERM UA9- University Paris-Saclay, Institut André Lwoff, Bâtiment A CNRS, 7 rue Guy Moquet, 94800 Villejuif, France.,ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, University Paris-Saclay, 94800 Villejuif, France.,Division of Hematology, APHP-Paris Saclay University Hospitals, Le Kremlin Bicêtre 94275, Villejuif 94800, France.,University Paris Saclay, Faculty of Medicine, Le Kremlin Bicêtre 94275, France
| | - Annelise Bennaceur-Griscelli
- INSERM UA9- University Paris-Saclay, Institut André Lwoff, Bâtiment A CNRS, 7 rue Guy Moquet, 94800 Villejuif, France.,ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, University Paris-Saclay, 94800 Villejuif, France.,Division of Hematology, APHP-Paris Saclay University Hospitals, Le Kremlin Bicêtre 94275, Villejuif 94800, France.,University Paris Saclay, Faculty of Medicine, Le Kremlin Bicêtre 94275, France
| | - Frank Griscelli
- INSERM UA9- University Paris-Saclay, Institut André Lwoff, Bâtiment A CNRS, 7 rue Guy Moquet, 94800 Villejuif, France.,ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, University Paris-Saclay, 94800 Villejuif, France.,University of Paris, Faculty Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France.,Gustave-Roussy Cancer Institute, Department of Biopathology, 94800 Villejuif, France
| |
Collapse
|
21
|
MacAldaz M, Bennaceur-Griscelli A, Eaves C, Kardel M, Miller P, Turhan A. 3105 – ENHANCED OUTPUT OF PRIMITIVE HEMATOPOIETIC CELL PHENOTYPES IN TERATOMAS GENERATED FROM HUMAN INDUCED PLURIPOTENT STEM CELLS (HIPSCS) IN MORE PERMISSIVE IMMUNODEFICIENT MICE. Exp Hematol 2020. [DOI: 10.1016/j.exphem.2020.09.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Hadadi E, Taylor W, Li XM, Aslan Y, Villote M, Rivière J, Duvallet G, Auriau C, Dulong S, Raymond-Letron I, Provot S, Bennaceur-Griscelli A, Acloque H. Chronic circadian disruption modulates breast cancer stemness and immune microenvironment to drive metastasis in mice. Nat Commun 2020; 11:3193. [PMID: 32581213 PMCID: PMC7314789 DOI: 10.1038/s41467-020-16890-6] [Citation(s) in RCA: 84] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Accepted: 05/29/2020] [Indexed: 12/24/2022] Open
Abstract
Breast cancer is the most common type of cancer worldwide and one of the major causes of cancer death in women. Epidemiological studies have established a link between night-shift work and increased cancer risk, suggesting that circadian disruption may play a role in carcinogenesis. Here, we aim to shed light on the effect of chronic jetlag (JL) on mammary tumour development. To do this, we use a mouse model of spontaneous mammary tumourigenesis and subject it to chronic circadian disruption. We observe that circadian disruption significantly increases cancer-cell dissemination and lung metastasis. It also enhances the stemness and tumour-initiating potential of tumour cells and creates an immunosuppressive shift in the tumour microenvironment. Finally, our results suggest that the use of a CXCR2 inhibitor could correct the effect of JL on cancer-cell dissemination and metastasis. Altogether, our data provide a conceptual framework to better understand and manage the effects of chronic circadian disruption on breast cancer progression. Circadian disruption is implicated in the development of different human cancers. Here the authors show that chronic circadian disruption, through continuous jet lag, only moderately affects primary tumour growth but promotes cancer-cell dissemination and metastasis in a mouse model of spontaneous mammary tumorigenesis.
Collapse
Affiliation(s)
- Eva Hadadi
- Inserm, U935, Université Paris Sud, Villejuif, France.
| | | | - Xiao-Mei Li
- Inserm, U935, Université Paris Sud, Villejuif, France.,Université Paris Sud, Université Paris Saclay, UFR de Médecine Kremlin Bicêtre, Le Kremlin-Bicêtre, France
| | - Yetki Aslan
- Inserm, U1132, Université Paris Diderot, Hôpital Lariboisière - Centre Viggo Petersen, 75010, Paris, France
| | - Marthe Villote
- GABI, INRA, AgroParisTech, Université Paris-Saclay, 78352, Jouy-en-Josas, France
| | - Julie Rivière
- GABI, INRA, AgroParisTech, Université Paris-Saclay, 78352, Jouy-en-Josas, France
| | | | | | - Sandrine Dulong
- Inserm, U935, Université Paris Sud, Villejuif, France.,Université Paris Sud, Université Paris Saclay, UFR de Médecine Kremlin Bicêtre, Le Kremlin-Bicêtre, France
| | - Isabelle Raymond-Letron
- Département des Sciences Biologiques et Fonctionnelles, Laboratoire d'HistoPathologie Expérimentale et Comparée (LabHPEC), ENVT, Université de Toulouse, Toulouse, France.,STROMALab, CNRS ERL5311, EFS, ENVT, Inserm U1031, Université de Toulouse, Toulouse, France
| | - Sylvain Provot
- Inserm, U1132, Université Paris Diderot, Hôpital Lariboisière - Centre Viggo Petersen, 75010, Paris, France
| | - Annelise Bennaceur-Griscelli
- Inserm, U935, Université Paris Sud, Villejuif, France.,Université Paris Sud, Université Paris Saclay, UFR de Médecine Kremlin Bicêtre, Le Kremlin-Bicêtre, France.,Service d'hématologie, APHP, GHU Paris Sud, Paris, France
| | - Hervé Acloque
- Inserm, U935, Université Paris Sud, Villejuif, France. .,GABI, INRA, AgroParisTech, Université Paris-Saclay, 78352, Jouy-en-Josas, France.
| |
Collapse
|
23
|
Pagliaro S, Desterke C, Acloque H, Chomel JC, de Souza L, Hugues P, Griscelli F, Foudi A, Bennaceur-Griscelli A, Turhan AG. Single-Cell Transcriptome in Chronic Myeloid Leukemia: Pseudotime Analysis Reveals Evidence of Embryonic and Transitional Stem Cell States. Exp Hematol 2020; 85:47-56.e2. [PMID: 32360510 DOI: 10.1016/j.exphem.2020.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Revised: 04/04/2020] [Accepted: 04/08/2020] [Indexed: 11/19/2022]
Abstract
Recent experimental data suggest that the heterogeneity of chronic myeloid leukemia (CML) stem cells may be the result of the development of unique molecular events generating functional consequences in terms of the resistance and persistence of leukemic stem cells. To explore this phenomenon, we designed a single-cell transcriptome assay evaluating simultaneously the expression of 87 genes. Highly purified CD34+ cells from three CML patients at diagnosis were immobilized in microfluidic chips, and the expression of 87 genes was evaluated in each cell. This analysis identified a group of 13 highly connected genes including NANOG, POU5F1, LIN28A, and SOX2, representing on average 8.59% of the cell population analyzed. Bioinformatics analysis with the corrected matrix and t-distributed stochastic neighbor embedding (tSNE) algorithm identified four distinct clusters, and the pseudotime analysis confirmed the presence of seven stem cell states in the four clusters identified. ALOX5 expression was associated with the group of cells expressing the pluripotency markers. In in vitro analyses, two genes that were predicted to undergo similar regulation using pseudotime analysis (ALOX5 and FGFR) were found to be similarly inhibited by ponatinib, an FGFR inhibitor. Finally, in an independent cohort of CML patients, we found that pluripotency gene expression is a common feature of CD34+ CML cells at diagnosis. Overall, these experiments allowed identification of individual CD34+ cells expressing high levels of pluripotency genes at diagnosis, in which a continuum of transitional states were identified using pseudotime analysis. These results suggest that leukemic stem cell persistence in CML needs to be targeted simultaneously rather than using a single pathway.
Collapse
MESH Headings
- Gene Expression Regulation, Leukemic
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/genetics
- Neoplastic Stem Cells/metabolism
- Neoplastic Stem Cells/pathology
- Single-Cell Analysis
- Transcriptome
Collapse
Affiliation(s)
- Sarah Pagliaro
- INSERM UMR-S 935, Villejuif, France; Sciencia Sem Fronteiras, CAPES, Brasilia, Brazil; Université Paris Saclay, France
| | | | | | | | | | | | - Frank Griscelli
- INSERM UMR-S 935, Villejuif, France; INGESTEM National iPSC Infrastructure, 94800 Villejuif, France; Université Paris Descartes, Faculté Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France
| | - Adlen Foudi
- ATIP-Avenir INSERM UMR-S 935, Université Paris Sud, 94800 Villejuif
| | - Annelise Bennaceur-Griscelli
- INSERM UMR-S 935, Villejuif, France; Université Paris Saclay, France; INGESTEM National iPSC Infrastructure, 94800 Villejuif, France
| | - Ali G Turhan
- INSERM UMR-S 935, Villejuif, France; Université Paris Saclay, France; INGESTEM National iPSC Infrastructure, 94800 Villejuif, France.
| |
Collapse
|
24
|
M’kacher R, Colicchio B, Borie C, Junker S, Marquet V, Heidingsfelder L, Soehnlen K, Najar W, Hempel WM, Oudrhiri N, Wilhelm-Murer N, Miguet M, Arnoux M, Ferrapie C, Kerbrat W, Plesch A, Dieterlen A, Girinsky T, Voisin P, Deschenes G, Tabet AC, Yardin C, Bennaceur-Griscelli A, Fenech M, Carde P, Jeandidier E. Telomere and Centromere Staining Followed by M-FISH Improves Diagnosis of Chromosomal Instability and Its Clinical Utility. Genes (Basel) 2020; 11:genes11050475. [PMID: 32349350 PMCID: PMC7291161 DOI: 10.3390/genes11050475] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 04/20/2020] [Accepted: 04/21/2020] [Indexed: 12/11/2022] Open
Abstract
Dicentric chromosomes are a relevant marker of chromosomal instability. Their appearance is associated with telomere dysfunction, leading to cancer progression and a poor clinical outcome. Here, we present Telomere and Centromere staining followed by M-FISH (TC+M-FISH) for improved detection of telomere dysfunction and the identification of dicentric chromosomes in cancer patients and various genetic syndromes. Significant telomere length shortening and significantly higher frequencies of telomere loss and deletion were found in the peripheral lymphocytes of patients with cancer and genetic syndromes relative to similar age-matched healthy donors. We assessed our technique against conventional cytogenetics for the detection of dicentric chromosomes by subjecting metaphase preparations to both approaches. We identified dicentric chromosomes in 28/50 cancer patients and 21/44 genetic syndrome patients using our approach, but only 7/50 and 12/44, respectively, using standard cytogenetics. We ascribe this discrepancy to the identification of the unique configuration of dicentric chromosomes. We observed significantly higher frequencies of telomere loss and deletion in patients with dicentric chromosomes (p < 10−4). TC+M-FISH analysis is superior to classical cytogenetics for the detection of chromosomal instability. Our approach is a relatively simple but useful tool for documenting telomere dysfunction and chromosomal instability with the potential to become a standard additional diagnostic tool in medical genetics and the clinic.
Collapse
Affiliation(s)
- Radhia M’kacher
- Cell Environment, DNA Damage R&D, 75020 Paris, France; (K.S.); (W.N.); (W.M.H.); (P.V.)
- Correspondence:
| | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France; (B.C.); (A.D.)
| | - Claire Borie
- APHP-Service D’hématologie Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/ Inserm UMR 935, 94800 Villejuif, France; (C.B.); (N.O.); (M.A.); (C.F.); (W.K.); (A.B.-G.)
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, DK-8000 Aarhus, Denmark;
| | - Valentine Marquet
- Service de Cytogénétique, Génétique Médicale, et Biologie de la Reproduction Hôpital de la Mère et de l’Enfant, CHU Dupuytren, 87042 Limoges, France; (V.M.); (C.Y.)
| | | | - Kevin Soehnlen
- Cell Environment, DNA Damage R&D, 75020 Paris, France; (K.S.); (W.N.); (W.M.H.); (P.V.)
| | - Wala Najar
- Cell Environment, DNA Damage R&D, 75020 Paris, France; (K.S.); (W.N.); (W.M.H.); (P.V.)
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France; (B.C.); (A.D.)
- APHP-Service D’hématologie Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/ Inserm UMR 935, 94800 Villejuif, France; (C.B.); (N.O.); (M.A.); (C.F.); (W.K.); (A.B.-G.)
- Institute of Biomedicine, University of Aarhus, DK-8000 Aarhus, Denmark;
- Service de Cytogénétique, Génétique Médicale, et Biologie de la Reproduction Hôpital de la Mère et de l’Enfant, CHU Dupuytren, 87042 Limoges, France; (V.M.); (C.Y.)
- MetaSystems GmbH, Robert-Bosch-Str., 6 D-68804 Altlussheim, Germany; (L.H.); (A.P.)
- Faculté de Médicine, Université Paris Descartes, 75005 Paris, France
| | - William M. Hempel
- Cell Environment, DNA Damage R&D, 75020 Paris, France; (K.S.); (W.N.); (W.M.H.); (P.V.)
| | - Noufissa Oudrhiri
- APHP-Service D’hématologie Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/ Inserm UMR 935, 94800 Villejuif, France; (C.B.); (N.O.); (M.A.); (C.F.); (W.K.); (A.B.-G.)
| | - Nadège Wilhelm-Murer
- Service de Génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace Mulhouse, 68070 Mulhouse, France; (N.W.-M.); (M.M.); (E.J.)
| | - Marguerite Miguet
- Service de Génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace Mulhouse, 68070 Mulhouse, France; (N.W.-M.); (M.M.); (E.J.)
| | - Micheline Arnoux
- APHP-Service D’hématologie Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/ Inserm UMR 935, 94800 Villejuif, France; (C.B.); (N.O.); (M.A.); (C.F.); (W.K.); (A.B.-G.)
| | - Catherine Ferrapie
- APHP-Service D’hématologie Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/ Inserm UMR 935, 94800 Villejuif, France; (C.B.); (N.O.); (M.A.); (C.F.); (W.K.); (A.B.-G.)
| | - Wendy Kerbrat
- APHP-Service D’hématologie Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/ Inserm UMR 935, 94800 Villejuif, France; (C.B.); (N.O.); (M.A.); (C.F.); (W.K.); (A.B.-G.)
| | - Andreas Plesch
- MetaSystems GmbH, Robert-Bosch-Str., 6 D-68804 Altlussheim, Germany; (L.H.); (A.P.)
| | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France; (B.C.); (A.D.)
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, 94800 Villejuif, France;
| | - Philippe Voisin
- Cell Environment, DNA Damage R&D, 75020 Paris, France; (K.S.); (W.N.); (W.M.H.); (P.V.)
| | - Georges Deschenes
- Nephrology Department, APHP-Hopital Robert Debré, 75019 Paris, France;
| | - Anne-Claude Tabet
- Cytogenetic Laboratory, APHP-Hopital Robert Debré, 75019 Paris, France;
| | - Catherine Yardin
- Service de Cytogénétique, Génétique Médicale, et Biologie de la Reproduction Hôpital de la Mère et de l’Enfant, CHU Dupuytren, 87042 Limoges, France; (V.M.); (C.Y.)
| | - Annelise Bennaceur-Griscelli
- APHP-Service D’hématologie Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/ Inserm UMR 935, 94800 Villejuif, France; (C.B.); (N.O.); (M.A.); (C.F.); (W.K.); (A.B.-G.)
| | - Michael Fenech
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5000, Australia;
- Genome Health Foundation, North Brighton, SA 5048, Australia
| | - Patrice Carde
- Department of Hematology, Gustave Roussy Cancer Campus, 94800 Villejuif, France;
| | - Eric Jeandidier
- Service de Génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace Mulhouse, 68070 Mulhouse, France; (N.W.-M.); (M.M.); (E.J.)
| |
Collapse
|
25
|
Turhan AG, Hugues P, Sorel N, Desterke C, Bourhis JH, Bennaceur-Griscelli A, Chomel JC. Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML). Leuk Lymphoma 2020; 61:1719-1723. [PMID: 32122205 DOI: 10.1080/10428194.2020.1734593] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Ali G Turhan
- INSERM UMR-S935, Campus CNRS, Villejuif, France.,Paris Saclay, Faculté de Médecine, Université Paris Sud, Le Kremlin-Bicêtre, France.,INGESTEM-ESTeam Paris Sud, Villejuif, France.,Service d'Onco-Hématologie, AP-HP Hôpitaux Universitaires Paris Sud, Hôpital Paul Brousse, Villejuif, France.,Service d'Hématologie, AP-HP Hôpitaux Universitaires Paris Sud, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | | | - Nathalie Sorel
- CHU de Poitiers, Service de Cancérologie Biologique, Poitiers, France
| | - Christophe Desterke
- INSERM UMR-S935, Campus CNRS, Villejuif, France.,Paris Saclay, Faculté de Médecine, Université Paris Sud, Le Kremlin-Bicêtre, France
| | | | - Annelise Bennaceur-Griscelli
- INSERM UMR-S935, Campus CNRS, Villejuif, France.,Paris Saclay, Faculté de Médecine, Université Paris Sud, Le Kremlin-Bicêtre, France.,INGESTEM-ESTeam Paris Sud, Villejuif, France.,Service d'Onco-Hématologie, AP-HP Hôpitaux Universitaires Paris Sud, Hôpital Paul Brousse, Villejuif, France.,Service d'Hématologie, AP-HP Hôpitaux Universitaires Paris Sud, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Jean-Claude Chomel
- INSERM UMR-S935, Campus CNRS, Villejuif, France.,CHU de Poitiers, Service de Cancérologie Biologique, Poitiers, France
| |
Collapse
|
26
|
D'Alessio R, Koukouli F, Blanchard S, Catteau J, Raïs C, Lemonnier T, Féraud O, Bennaceur-Griscelli A, Groszer M, Maskos U. Long-term development of human iPSC-derived pyramidal neurons quantified after transplantation into the neonatal mouse cortex. Dev Biol 2020; 461:86-95. [PMID: 31982375 DOI: 10.1016/j.ydbio.2020.01.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2019] [Revised: 12/26/2019] [Accepted: 01/17/2020] [Indexed: 11/26/2022]
Abstract
One of the main obstacles for studying the molecular and cellular mechanisms underlying human neurodevelopment in vivo is the scarcity of experimental models. The discovery that neurons can be generated from human induced pluripotent stem cells (hiPSCs) paves the way for novel approaches that are stem cell-based. Here, we developed a technique to follow the development of transplanted hiPSC-derived neuronal precursors in the cortex of mice over time. Using post-mortem immunohistochemistry we quantified the differentiation and maturation of dendritic patterns of the human neurons over a total of six months. In addition, entirely hiPSC-derived neuronal parenchyma was followed over eight months using two-photon in vivo imaging through a cranial window. We found that transplanted hiPSC-derived neuronal precursors exhibit a "protracted" human developmental programme in different cortical areas. This offers novel possibilities for the sequential in vivo study of human cortical development and its alteration, followed in "real time".
Collapse
Affiliation(s)
- Rosa D'Alessio
- Institut Pasteur, Neurobiologie Intégrative des Systèmes Cholinergiques, Département de Neuroscience, CNRS UMR 3571, 25 rue du Dr Roux, 75724, Paris Cedex 15, France
| | - Fani Koukouli
- Institut Pasteur, Neurobiologie Intégrative des Systèmes Cholinergiques, Département de Neuroscience, CNRS UMR 3571, 25 rue du Dr Roux, 75724, Paris Cedex 15, France; Sorbonne Université, Collège Doctoral, 75005, Paris, France
| | - Stéphane Blanchard
- Institut Pasteur, Neurobiologie Intégrative des Systèmes Cholinergiques, Département de Neuroscience, CNRS UMR 3571, 25 rue du Dr Roux, 75724, Paris Cedex 15, France
| | - Julie Catteau
- Institut Pasteur, Neurobiologie Intégrative des Systèmes Cholinergiques, Département de Neuroscience, CNRS UMR 3571, 25 rue du Dr Roux, 75724, Paris Cedex 15, France
| | - Célia Raïs
- Institut Pasteur, Neurobiologie Intégrative des Systèmes Cholinergiques, Département de Neuroscience, CNRS UMR 3571, 25 rue du Dr Roux, 75724, Paris Cedex 15, France; Sorbonne Université, Collège Doctoral, 75005, Paris, France
| | - Thomas Lemonnier
- Institut du Fer à Moulin, Sorbonne Université, INSERM UMR-S 1270, 75005, Paris, France
| | - Olivier Féraud
- INSERM UMR 935, ESTeam Paris Sud, SFR André Lwoff, Université Paris Sud, Villejuif, France; Infrastructure Nationale INGESTEM, Université Paris Sud, INSERM, Paris, France
| | - Annelise Bennaceur-Griscelli
- INSERM UMR 935, ESTeam Paris Sud, SFR André Lwoff, Université Paris Sud, Villejuif, France; Infrastructure Nationale INGESTEM, Université Paris Sud, INSERM, Paris, France
| | - Matthias Groszer
- Institut du Fer à Moulin, Sorbonne Université, INSERM UMR-S 1270, 75005, Paris, France
| | - Uwe Maskos
- Institut Pasteur, Neurobiologie Intégrative des Systèmes Cholinergiques, Département de Neuroscience, CNRS UMR 3571, 25 rue du Dr Roux, 75724, Paris Cedex 15, France.
| |
Collapse
|
27
|
Hwang JW, Loisel-Duwattez J, Desterke C, Latsis T, Pagliaro S, Griscelli F, Bennaceur-Griscelli A, Turhan AG. A novel neuronal organoid model mimicking glioblastoma (GBM) features from induced pluripotent stem cells (iPSC). Biochim Biophys Acta Gen Subj 2020; 1864:129540. [PMID: 31978452 DOI: 10.1016/j.bbagen.2020.129540] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Revised: 01/07/2020] [Accepted: 01/17/2020] [Indexed: 12/18/2022]
Abstract
BACKGROUND Current experimental models using either human or mouse cell lines, are not representative of the complex features of GBM. In particular, there is no model to study patient-derived iPSCs to generate a GBM model. Overexpression of c-met gene is one of the molecular features of GBM leading to increased signaling via STAT3 phosphorylation. We generated an iPSC line from a patient with c-met mutation and we asked whether we could use it to generate neuronal-like organoids mimicking features of GBM. METHODS We have generated iPSC-aggregates differentiating towards organoids. We analyzed them by gene expression profiling, immunostaining and transmission electronic microscopy analyses (TEM). RESULTS Herein we describe that c-met-mutated iPSC aggregates spontaneously differentiate into dopaminergic neurons more rapidly than control iPSC aggregates in culture. Gene expression profiling of c-met-mutated iPSC aggregates at day +90 showed neuronal- and GBM-related genes, reproducing a genomic network described in primary human GBM. Comparative TEM analyses confirmed the enrichment of these structures in intermediate filaments and abnormal cilia, a feature described in human GBM. The c-met-mutated iPSC-derived organoids, as compared to controls expressed high levels of glial fibrillary acidic protein (GFAP), which is a typical marker of human GBM, as well as high levels of phospho-MET and phospho-STAT3. The use of temozolomide (TMZ) showed a preferential cytotoxicity of this drug in c-met-mutated neuronal-like organoids. GENERAL SIGNIFICANCE This study shows the feasibility of generating "off-the shelf" neuronal-like organoid model mimicking GBM using c-met-mutated iPSC aggregates and its potential future use in research.
Collapse
Affiliation(s)
- Jin Wook Hwang
- INSERM UMR-S 935, Université Paris Sud, 94800 Villejuif, France; ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France
| | - Julien Loisel-Duwattez
- INSERM U1195, Université Paris Sud, Faculté de Médecine, APHP, Service de Neurologie, Bicêtre Hospital, 94276 le Kremlin Bicêtre, France
| | - Christophe Desterke
- INSERM UMR-S 935, Université Paris Sud, 94800 Villejuif, France; ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France
| | - Theodoros Latsis
- INSERM UMR-S 935, Université Paris Sud, 94800 Villejuif, France; ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France
| | - Sarah Pagliaro
- INSERM UMR-S 935, Université Paris Sud, 94800 Villejuif, France; ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France
| | - Frank Griscelli
- INSERM UMR-S 935, Université Paris Sud, 94800 Villejuif, France; ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France
| | | | - Ali G Turhan
- INSERM UMR-S 935, Université Paris Sud, 94800 Villejuif, France; INGESTEM National IPSC Infrastructure, 94800 Villejuif, France; Division of Hematology, Paris Sud University Hospitals, Le Kremlin Bicêtre 75006, Villejuif 94800, France; ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France.
| |
Collapse
|
28
|
Hwang JW, Desterke C, Féraud O, Richard S, Ferlicot S, Verkarre V, Patard JJ, Loisel-Duwattez J, Foudi A, Griscelli F, Bennaceur-Griscelli A, Turhan AG. iPSC-Derived Embryoid Bodies as Models of c- Met-Mutated Hereditary Papillary Renal Cell Carcinoma. Int J Mol Sci 2019; 20:ijms20194867. [PMID: 31575031 PMCID: PMC6801716 DOI: 10.3390/ijms20194867] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2019] [Revised: 09/23/2019] [Accepted: 09/24/2019] [Indexed: 12/19/2022] Open
Abstract
Hereditary cancers with cancer-predisposing mutations represent unique models of human oncogenesis, as a driving oncogenic event is present in germline. Currently, there are no satisfactory models to study these malignancies. We report the generation of IPSC from the somatic cells of a patient with hereditary c-met-mutated papillary renal cell carcinoma (PRCC). From these cells we have generated spontaneous aggregates organizing in structures which expressed kidney markers such as PODXL and Six2. These structures expressed PRCC markers both in vitro and in vivo in NSG mice. Gene-expression profiling showed striking molecular similarities with signatures found in a large cohort of PRCC tumor samples. This analysis, applied to primary cancers with and without c-met mutation, showed overexpression of the BHLHE40 and KDM4C only in the c-met-mutated PRCC tumors, as predicted by c-met-mutated embryoid bodies transcriptome. These data therefore represent the first proof of concept of “hereditary renal cancer in a dish” model using c-met-mutated iPSC-derived embryoid bodies, opening new perspectives for discovery of novel predictive progression markers and for drug-screening for future precision-medicine strategies.
Collapse
Affiliation(s)
- Jin Wook Hwang
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France.
| | - Christophe Desterke
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France.
| | - Olivier Féraud
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France.
| | - Stephane Richard
- Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR, labellisé par l'INCa, et Service d'Urologie, AP-HP, Hôpital Bicêtre, 94270 Le Kremlin-Bicêtre, France; Génétique Oncologique EPHE, PSL Université, INSERM UMR 1186, Gustave Roussy, Faculté de Médecine et Université Paris-Sud, 94800 Villejuif, France.
| | - Sophie Ferlicot
- INSERM, UMR 1186, Gustave Roussy, Paris-Sud University, Paris-Saclay University, 94800 Villejuif, France.
- Department of Pathology, Bicêtre Hospital, AP-HP, 94270 Le Kremlin-Bicêtre, France.
| | - Virginie Verkarre
- Service d'Anatomie Pathologique, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France.
- Faculté de médecine, Université Paris Descartes, 75006 Paris, France.
| | - Jean Jacques Patard
- Service d'Urologie, Centre Hospitalier de Mont de Marsan, 40024 Mont de Marsan, France.
| | - Julien Loisel-Duwattez
- INSERM U1195, Université Paris Sud, Faculté de Médecine, APHP, Service de Neurologie, Hôpital Bicêtre, 94276 le Kremlin Bicêtre, France.
| | - Adlen Foudi
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France.
- ATIP Avenir INSERM UMR-S 935, Université Paris Sud, 94800 Villejuif, France.
| | - Frank Griscelli
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France.
- INGESTEM National IPSC Infrastructure, 94800 Villejuif, France.
- Paris Descartes University, Faculty Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, 75006 Paris, France.
| | - Annelise Bennaceur-Griscelli
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France.
- INGESTEM National IPSC Infrastructure, 94800 Villejuif, France.
- Division of Hematology, Paris Sud University Hospitals, Le Kremlin Bicêtre 75006, 94800 Villejuif, France.
| | - Ali G Turhan
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, 94800 Villejuif, France.
- INGESTEM National IPSC Infrastructure, 94800 Villejuif, France.
- Division of Hematology, Paris Sud University Hospitals, Le Kremlin Bicêtre 75006, 94800 Villejuif, France.
| |
Collapse
|
29
|
Balducci E, Sanekli S, Hugues P, Soubeyrand M, Borie C, Fund X, Desterke C, Aumont C, Faivre J, Bennaceur-Griscelli A, Turhan AG. Co-occurrence of BCR-ABL1 rearrangement and CALR mutation in a single leukemic stem cell: evidence that BCR-ABL1 oncogenic addiction prevails over CALR signaling. Leuk Lymphoma 2019; 61:209-212. [PMID: 31464171 DOI: 10.1080/10428194.2019.1658101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Estelle Balducci
- INSERM, Unité Mixte de Recherche (UMR) 935, Villejuif, France.,Assistance Publique-Hôpitaux de Paris, Service D'Hématologie, Hôpital Paul Brousse, Villejuif, France
| | - Safa Sanekli
- INSERM, Unité Mixte de Recherche (UMR) 935, Villejuif, France.,Assistance Publique-Hôpitaux de Paris, Service D'Hématologie, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Patricia Hugues
- INSERM, Unité Mixte de Recherche (UMR) 935, Villejuif, France
| | | | - Claire Borie
- Assistance Publique-Hôpitaux de Paris, Service D'Hématologie, Hôpital Paul Brousse, Villejuif, France
| | - Xavier Fund
- Assistance Publique-Hôpitaux de Paris, Service D'Hématologie, Hôpital Paul Brousse, Villejuif, France
| | - Christophe Desterke
- INSERM, Unité Mixte de Recherche (UMR) 935, Villejuif, France.,Assistance Publique-Hôpitaux de Paris, Service D'Hématologie, Hôpital Paul Brousse, Villejuif, France
| | - Cédric Aumont
- Assistance Publique-Hôpitaux de Paris, Service D'Hématologie, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Jamila Faivre
- Assistance Publique-Hôpitaux de Paris, Service D'Hématologie, Hôpital Paul Brousse, Villejuif, France.,INSERM, UMR 785, Centre Hépato-Biliaire, Villejuif, France
| | - Annelise Bennaceur-Griscelli
- INSERM, Unité Mixte de Recherche (UMR) 935, Villejuif, France.,Assistance Publique-Hôpitaux de Paris, Service D'Hématologie, Hôpital Paul Brousse, Villejuif, France.,Assistance Publique-Hôpitaux de Paris, Service D'Hématologie, Hôpital Bicêtre, Le Kremlin Bicêtre, France.,INGESTEM-ESteam Pluripotent Stem Cell Infrastructure, Villejuif, France
| | - Ali G Turhan
- INSERM, Unité Mixte de Recherche (UMR) 935, Villejuif, France.,Assistance Publique-Hôpitaux de Paris, Service D'Hématologie, Hôpital Paul Brousse, Villejuif, France.,Assistance Publique-Hôpitaux de Paris, Service D'Hématologie, Hôpital Bicêtre, Le Kremlin Bicêtre, France.,INGESTEM-ESteam Pluripotent Stem Cell Infrastructure, Villejuif, France
| |
Collapse
|
30
|
Hirose T, Cabrera-Socorro A, Chitayat D, Lemonnier T, Féraud O, Cifuentes-Diaz C, Gervasi N, Mombereau C, Ghosh T, Stoica L, Bacha JDA, Yamada H, Lauterbach MA, Guillon M, Kaneko K, Norris JW, Siriwardena K, Blasér S, Teillon J, Mendoza-Londono R, Russeau M, Hadoux J, Ito S, Corvol P, Matheus MG, Holden KR, Takei K, Emiliani V, Bennaceur-Griscelli A, Schwartz CE, Nguyen G, Groszer M. ATP6AP2 variant impairs CNS development and neuronal survival to cause fulminant neurodegeneration. J Clin Invest 2019; 129:2145-2162. [PMID: 30985297 DOI: 10.1172/jci79990] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Accepted: 03/05/2019] [Indexed: 12/31/2022] Open
Abstract
Vacuolar H+-ATPase-dependent (V-ATPase-dependent) functions are critical for neural proteostasis and are involved in neurodegeneration and brain tumorigenesis. We identified a patient with fulminant neurodegeneration of the developing brain carrying a de novo splice site variant in ATP6AP2 encoding an accessory protein of the V-ATPase. Functional studies of induced pluripotent stem cell-derived (iPSC-derived) neurons from this patient revealed reduced spontaneous activity and severe deficiency in lysosomal acidification and protein degradation leading to neuronal cell death. These deficiencies could be rescued by expression of full-length ATP6AP2. Conditional deletion of Atp6ap2 in developing mouse brain impaired V-ATPase-dependent functions, causing impaired neural stem cell self-renewal, premature neuronal differentiation, and apoptosis resulting in degeneration of nearly the entire cortex. In vitro studies revealed that ATP6AP2 deficiency decreases V-ATPase membrane assembly and increases endosomal-lysosomal fusion. We conclude that ATP6AP2 is a key mediator of V-ATPase-dependent signaling and protein degradation in the developing human central nervous system.
Collapse
Affiliation(s)
- Takuo Hirose
- Collège de France, Center for Interdisciplinary Research in Biology, Paris, France
| | - Alfredo Cabrera-Socorro
- INSERM, UMR-S 1270, Paris, France.,Sorbonne Université, Paris, France.,Institut du Fer à Moulin, Paris, France
| | - David Chitayat
- Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.,Division of Clinical and Metabolic Genetics and.,Department of Diagnostic Imaging, Division of Pediatric Neuroradiology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
| | - Thomas Lemonnier
- INSERM, UMR-S 1270, Paris, France.,Sorbonne Université, Paris, France.,Institut du Fer à Moulin, Paris, France
| | - Olivier Féraud
- INSERM, UMR 935, ESTeam Paris Sud, SFR André Lwoff, Université Paris Sud, Villejuif, France.,Infrastructure Nationale INGESTEM, Université Paris Sud, INSERM, Paris, France
| | - Carmen Cifuentes-Diaz
- INSERM, UMR-S 1270, Paris, France.,Sorbonne Université, Paris, France.,Institut du Fer à Moulin, Paris, France
| | - Nicolas Gervasi
- INSERM, UMR-S 1270, Paris, France.,Sorbonne Université, Paris, France.,Institut du Fer à Moulin, Paris, France
| | - Cedric Mombereau
- INSERM, UMR-S 1270, Paris, France.,Sorbonne Université, Paris, France.,Institut du Fer à Moulin, Paris, France
| | - Tanay Ghosh
- INSERM, UMR-S 1270, Paris, France.,Sorbonne Université, Paris, France.,Institut du Fer à Moulin, Paris, France
| | - Loredana Stoica
- INSERM, UMR-S 1270, Paris, France.,Sorbonne Université, Paris, France.,Institut du Fer à Moulin, Paris, France
| | - Jeanne d'Arc Al Bacha
- Collège de France, Center for Interdisciplinary Research in Biology, Paris, France.,Sorbonne Université, Paris, France.,Institut du Fer à Moulin, Paris, France.,Laboratory of Applied Biotechnology, Azm Center for the Research in Biotechnology and Its Applications, Doctoral School for Sciences and Technology, Lebanese University, Tripoli, Lebanon.,Reviva Regenerative Medicine Center, Human Genetic Center, Middle East Institute of Health Hospital, Bsalim, Lebanon
| | - Hiroshi Yamada
- Department of Neuroscience, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Marcel A Lauterbach
- Wavefront-Engineering Microscopy Group, Neurophotonics Laboratory, CNRS, UMR 8250, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Marc Guillon
- Wavefront-Engineering Microscopy Group, Neurophotonics Laboratory, CNRS, UMR 8250, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Kiriko Kaneko
- Department of Endocrinology and Applied Medical Science, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Joy W Norris
- Greenwood Genetic Center, Greenwood, South Carolina, USA
| | | | | | - Jérémie Teillon
- Collège de France, Center for Interdisciplinary Research in Biology, Paris, France.,INSERM, U1050, Paris, France.,CNRS, UMR 7241, Paris, France
| | | | - Marion Russeau
- INSERM, UMR-S 1270, Paris, France.,Sorbonne Université, Paris, France.,Institut du Fer à Moulin, Paris, France
| | - Julien Hadoux
- INSERM, UMR 935, ESTeam Paris Sud, SFR André Lwoff, Université Paris Sud, Villejuif, France.,Infrastructure Nationale INGESTEM, Université Paris Sud, INSERM, Paris, France
| | - Sadayoshi Ito
- Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Pierre Corvol
- Collège de France, Center for Interdisciplinary Research in Biology, Paris, France.,INSERM, U1050, Paris, France.,CNRS, UMR 7241, Paris, France
| | | | - Kenton R Holden
- Department of Radiology, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Kohji Takei
- Department of Neuroscience, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Valentina Emiliani
- Wavefront-Engineering Microscopy Group, Neurophotonics Laboratory, CNRS, UMR 8250, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Annelise Bennaceur-Griscelli
- INSERM, UMR 935, ESTeam Paris Sud, SFR André Lwoff, Université Paris Sud, Villejuif, France.,Infrastructure Nationale INGESTEM, Université Paris Sud, INSERM, Paris, France.,Faculté de Médecine, Kremlin-Bicêtre, Université Paris Sud, Paris Saclay, France.,AP-HP, Service d'Hématologie, Hôpitaux Universitaires Paris Sud, Hôpital Paul Brousse, Villejuif, France
| | | | - Genevieve Nguyen
- Collège de France, Center for Interdisciplinary Research in Biology, Paris, France.,INSERM, U1050, Paris, France.,CNRS, UMR 7241, Paris, France
| | - Matthias Groszer
- INSERM, UMR-S 1270, Paris, France.,Sorbonne Université, Paris, France.,Institut du Fer à Moulin, Paris, France
| |
Collapse
|
31
|
Turhan A, Foudi A, Hwang JW, Desterke C, Griscelli F, Bennaceur-Griscelli A. Modeling malignancies using induced pluripotent stem cells: from chronic myeloid leukemia to hereditary cancers. Exp Hematol 2019; 71:61-67. [PMID: 30659851 DOI: 10.1016/j.exphem.2019.01.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Revised: 01/07/2019] [Accepted: 01/11/2019] [Indexed: 11/18/2022]
Abstract
Over the last decade, the possibility of reprogramming malignant cells to a pluripotent state has been achieved in several hematological malignancies, including myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia (CML). It has been shown that it is readily possible to generate induced pluripotent stem cells (iPSCs) from several types of primary CML cells and to generate progenitors and differentiated cells with variable efficiency. Although these experiments have brought some new insights in the understanding of CML pathophysiology, the ultimate goal of generating induced leukemic stem cells (LSCs) with long-term multilineage potential has not yet been demonstrated. Experiments under way will determine whether additional signaling events are required to induce the emergence of bona fide LSCs. However, iPSC modeling offers the unique possibility to generate pluripotent cells harboring cancer-predisposing mutations using patient-derived noncancerous cells, as has been shown in Li-Fraumeni syndrome, BRCA-1 associated breast carcinomas, or RET-mutated medullary thyroid carcinomas. In these conditions, mutated iPSCs can then be used to study the mutational history that precedes the appearance of the malignant transformation and to develop novel drug-screening strategies. The ability to induce a successful differentiation program toward the tissue in which a given cancer develops or to generate tissue-specific cancer organoids in which the full oncogenic potential can be revealed remains a major challenge in the field. Similarly, in hematological malignancies, a significant hurdle remains due to the lack of adequate technology to induce the emergence of leukemic cells that resemble LSCs, which hinders our ability to study the mechanisms of therapy resistance.
Collapse
MESH Headings
- Animals
- Biomarkers
- Cell Differentiation
- Cell Transformation, Neoplastic/genetics
- Cell Transformation, Neoplastic/metabolism
- Disease Susceptibility
- Humans
- Induced Pluripotent Stem Cells/cytology
- Induced Pluripotent Stem Cells/metabolism
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/etiology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Models, Biological
- Neoplastic Syndromes, Hereditary/etiology
- Neoplastic Syndromes, Hereditary/metabolism
- Neoplastic Syndromes, Hereditary/pathology
- Tumor Microenvironment
Collapse
Affiliation(s)
- Ali Turhan
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, Villejuif, France; INGESTEM National iPSC Infrastructure, Villejuif, France.
| | - Adlen Foudi
- ATIP-Avenir INSERM UMR-S 935, Université Paris Sud, Villejuif, France
| | - Jin Wook Hwang
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, Villejuif, France
| | - Christophe Desterke
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, Villejuif, France
| | - Frank Griscelli
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, Villejuif, France; INGESTEM National iPSC Infrastructure, Villejuif, France; Université Paris Descartes, Faculté Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France
| | - Annelise Bennaceur-Griscelli
- INSERM UMR-S 935 and ESTeam Paris Sud, Université Paris Sud, Villejuif, France; INGESTEM National iPSC Infrastructure, Villejuif, France
| |
Collapse
|
32
|
Zhang Y, Clay D, Mitjavila-Garcia MT, Alama A, Mennesson B, Berseneff H, Louache F, Bennaceur-Griscelli A, Oberlin E. VE-Cadherin and ACE Co-Expression Marks Highly Proliferative Hematopoietic Stem Cells in Human Embryonic Liver. Stem Cells Dev 2019; 28:165-185. [PMID: 30426841 DOI: 10.1089/scd.2018.0154] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Despite advances to engineer transplantable hematopoietic stem and progenitor cells (HSPCs) for research and therapy, an in-depth characterization of the developing human hematopoietic system is still lacking. The human embryonic liver is at the crossroad of several hematopoietic sites and harbors a complex hematopoietic hierarchy, including the first actively dividing HSPCs that will further seed the definitive hematopoietic organs. However, few are known about the phenotypic and functional HSPC organization operating at these stages of development. In this study, using a combination of four endothelial and hematopoietic surface markers, that is, the endothelial-specific marker vascular endothelial-cadherin (Cdh5, CD144), the pan-leukocyte antigen CD45, the hemato-endothelial marker CD34, and the angiotensin-converting enzyme (ACE, CD143), we identified distinct HSPC subsets, and among them, a population co-expressing the four markers that uniquely harbored an outstanding proliferation potential both ex vivo and in vivo. Moreover, we traced back this population to the yolk sac (YS) and aorta-gonad-mesonephros (AGM) sites of hematopoietic emergence. Taken together, our data will help to identify human HSPC self-renewal and amplification mechanisms for future cell therapies.
Collapse
Affiliation(s)
- Yanyan Zhang
- 1 Inserm, UMR 1170, Villejuif, France.,2 Paris-Saclay University, Villejuif, France.,3 Gustave Roussy, Villejuif, France
| | - Denis Clay
- 4 Inserm UMS 33, Villejuif, France.,5 André Lwoff Institute (IFR89), Villejuif, France.,6 Paris-Saclay University, Villejuif, France
| | - Maria Teresa Mitjavila-Garcia
- 5 André Lwoff Institute (IFR89), Villejuif, France.,6 Paris-Saclay University, Villejuif, France.,7 Inserm UMR 935, Villejuif, France
| | - Aurélie Alama
- 5 André Lwoff Institute (IFR89), Villejuif, France.,6 Paris-Saclay University, Villejuif, France.,7 Inserm UMR 935, Villejuif, France
| | - Benoit Mennesson
- 8 Obstetrics and Gynecology Department, René-Dubos Hospital, Pontoise, France
| | - Helene Berseneff
- 8 Obstetrics and Gynecology Department, René-Dubos Hospital, Pontoise, France
| | - Fawzia Louache
- 1 Inserm, UMR 1170, Villejuif, France.,2 Paris-Saclay University, Villejuif, France.,3 Gustave Roussy, Villejuif, France
| | - Annelise Bennaceur-Griscelli
- 5 André Lwoff Institute (IFR89), Villejuif, France.,6 Paris-Saclay University, Villejuif, France.,7 Inserm UMR 935, Villejuif, France
| | - Estelle Oberlin
- 5 André Lwoff Institute (IFR89), Villejuif, France.,6 Paris-Saclay University, Villejuif, France.,7 Inserm UMR 935, Villejuif, France
| |
Collapse
|
33
|
Janot C, Feriel J, Borie C, Lefevre E, Bennaceur-Griscelli A, Turhan AG, Aumont C. Clinically silent indolent T-cell leukemia. Clin Case Rep 2018; 7:24-26. [PMID: 30656001 PMCID: PMC6332809 DOI: 10.1002/ccr3.1528] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Accepted: 03/05/2018] [Indexed: 11/16/2022] Open
Abstract
The clinically silent, symptom‐free T‐cell prolymphocytic leukemia case that we report here confirms the major interest of the analysis of the blood smear as usual care of any emergent lymphocytosis. It also brings out the issue of the monitoring and follow‐up of this uncommon presentation.
Collapse
Affiliation(s)
- Clément Janot
- Division of Hematology Centre Hospitalier Universitaire Université Paris Sud 11 Le Kremlin Bicêtre France
| | - Joffrey Feriel
- Division of Hematology Centre Hospitalier Universitaire Université Paris Sud 11 Le Kremlin Bicêtre France.,INSERM U935, Campus CNRS Villejuif France
| | - Claire Borie
- Division of Hematology Centre Hospitalier Universitaire Université Paris Sud 11 Le Kremlin Bicêtre France.,INSERM U935, Campus CNRS Villejuif France
| | - Edouard Lefevre
- Department of Internal Medecine Centre Hospitalier Universitaire Université Paris Sud 11 Le Kremlin Bicêtre France
| | - Annelise Bennaceur-Griscelli
- Division of Hematology Centre Hospitalier Universitaire Université Paris Sud 11 Le Kremlin Bicêtre France.,INSERM U935, Campus CNRS Villejuif France
| | - Ali G Turhan
- Division of Hematology Centre Hospitalier Universitaire Université Paris Sud 11 Le Kremlin Bicêtre France.,INSERM U935, Campus CNRS Villejuif France
| | - Cédric Aumont
- Division of Hematology Centre Hospitalier Universitaire Université Paris Sud 11 Le Kremlin Bicêtre France.,INSERM U935, Campus CNRS Villejuif France
| |
Collapse
|
34
|
M'kacher R, Frenzel M, Al Jawhari M, Junker S, Cuceu C, Morat L, Bauchet AL, Stimmer L, Lenain A, Dechamps N, Hempel WM, Pottier G, Heidingsfelder L, Laplagne E, Borie C, Oudrhiri N, Jouni D, Bennaceur-Griscelli A, Colicchio B, Dieterlen A, Girinsky T, Boisgard R, Bourhis J, Bosq J, Mehrling T, Jeandidier E, Carde P. Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies. Cancers (Basel) 2018; 10:cancers10110414. [PMID: 30384446 PMCID: PMC6265845 DOI: 10.3390/cancers10110414] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 10/25/2018] [Accepted: 10/26/2018] [Indexed: 01/16/2023] Open
Abstract
To identify the cells responsible for the initiation and maintenance of Hodgkin lymphoma (HL) cells, we have characterized a subpopulation of HL cells grown in vitro and in vivo with the aim of establishing a reliable and robust animal model for HL. To validate our model, we challenged the tumor cells in vivo by injecting the alkylating histone-deacetylase inhibitor, EDO-S101, a salvage regimen for HL patients, into xenografted mice. Methodology: Blood lymphocytes from 50 HL patients and seven HL cell lines were used. Immunohistochemistry, flow cytometry, and cytogenetics analyses were performed. The in vitro and in vivo effects of EDO-S101 were assessed. Results: We have successfully determined conditions for in vitro amplification and characterization of the HL L428-c subline, containing a higher proportion of CD30−/CD15− cells than the parental L428 cell line. This subline displayed excellent clonogenic potential and reliable reproducibility upon xenografting into immunodeficient NOD-SCID-gamma (−/−)(NSG) mice. Using cell sorting, we demonstrate that CD30−/CD15− subpopulations can gain the phenotype of the L428-c cell line in vitro. Moreover, the human cells recovered from the seventh week after injection of L428-c cells into NSG mice were small cells characterized by a high frequency of CD30−/CD15− cells. Cytogenetic analysis demonstrated that they were diploid and showed high telomere instability and telomerase activity. Accordingly, chromosomal instability emerged, as shown by the formation of dicentric chromosomes, ring chromosomes, and breakage/fusion/bridge cycles. Similarly, high telomerase activity and telomere instability were detected in circulating lymphocytes from HL patients. The beneficial effect of the histone-deacetylase inhibitor EDO-S101 as an anti-tumor drug validated our animal model. Conclusion: Our HL animal model requires only 103 cells and is characterized by a high survival/toxicity ratio and high reproducibility. Moreover, the cells that engraft in mice are characterized by a high frequency of small CD30−/CD15− cells exhibiting high telomerase activity and telomere dysfunction.
Collapse
Affiliation(s)
- Radhia M'kacher
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
- Cell Environment, Oncology Section, 75020 Paris, France.
| | - Monika Frenzel
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Mustafa Al Jawhari
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, DK-8000 Aarhus C, Denmark.
| | - Corina Cuceu
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Luc Morat
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Anne-Laure Bauchet
- Platform for Experimental Pathology PathEX/CRC MIRCen/CEA-INSERM, University Paris-Saclay, 92265 Fontenay aux Rroses, France.
| | - Lev Stimmer
- Platform for Experimental Pathology PathEX/CRC MIRCen/CEA-INSERM, University Paris-Saclay, 92265 Fontenay aux Rroses, France.
| | - Aude Lenain
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Nathalie Dechamps
- Platform for Cell Sorting, CEA, iRCM, 92265 Fontenay aux Roses, France.
| | - William M Hempel
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Geraldine Pottier
- Laboratoire d'Imagerie Moléculaire Expérimentale Groupe d'Imagerie du Petit Animal CEA/DSV/I2BM/SHFJ/U1023, University Paris-Saclay, 91400 Orsay, France.
| | | | | | - Claire Borie
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | - Noufissa Oudrhiri
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | - Dima Jouni
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | | | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| | - Raphael Boisgard
- Laboratoire d'Imagerie Moléculaire Expérimentale Groupe d'Imagerie du Petit Animal CEA/DSV/I2BM/SHFJ/U1023, University Paris-Saclay, 91400 Orsay, France.
| | - Jean Bourhis
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| | - Jacques Bosq
- Departement of Anapathology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Vilejuif, France.
| | | | - Eric Jeandidier
- Department of Genetic, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, 68093 Mulhouse, France.
| | - Patrice Carde
- Department of Medicine, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| |
Collapse
|
35
|
Hadadi E, Souza LEBD, Bennaceur-Griscelli A, Acloque H. Identification of valid reference genes for circadian gene-expression studies in human mammary epithelial cells. Chronobiol Int 2018; 35:1689-1701. [PMID: 30296179 DOI: 10.1080/07420528.2018.1508151] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The circadian clock controls most of the physiological processes in the body throughout days and nights' alternation. Its dysregulation has a negative impact on many aspects of human health, such as obesity, lipid disorders, diabetes, skin regeneration, hematopoiesis and cancer. To date, poor is known on the molecular mechanisms that links mammary gland homeostasis to the circadian clock but recent reports highlight the importance of loss of circadian genes for mammary gland development and during tumour progression in breast cancer. Gene expression studies are then required to clarify how the circadian clock can modulates the human mammary gland development during ontology and its behaviour in physiological and oncogenic context. For this, in addition to genome-wide studies, real-time quantitative RT-PCR (qPCR) is a powerful and pertinent technique to quantify the expression of a reduced set of genes of interest in many different samples. Relative quantification of qPCR data requires the use of reference genes for normalisation. For circadian studies, reference genes expression must not oscillate in mirror of the circadian clock and must not be affected by the synchronisation protocols required in vitro to reset the circadian clock. Inappropriate selection of reference genes can consequently affect the amplitude of gene expression oscillation and bias data interpretation. Currently, no standard reference genes have been validated regarding these criteria for human mammary epithelial cells and the purpose of this study was to fill this gap. For this, we used the RefFinder tool, which combines four different algorithms, on 9 candidate reference genes. We compared reference genes stability using three different synchronisation protocols applied on four different mammary epithelial cell lines. This allowed us to define a set of reference genes in human mammary epithelial cells whose expression remains stable despite synchronisation protocols. We observed that the synchronisation of cells by serum shock was the most suitable procedure for maintaining the amplitude of oscillation of clock genes over time and we identified RPL4, RPLP0, HSPCB and TBP as an optimal combination of reference genes for the normalisation of the oscillatory expression of clock genes in human mammary epithelial cells.
Collapse
Affiliation(s)
- Eva Hadadi
- a Inserm, UMRS935 ESTeam Paris Sud, Malignant and Therapeutic Stem Cell Models , Villejuif , France
| | | | - Annelise Bennaceur-Griscelli
- a Inserm, UMRS935 ESTeam Paris Sud, Malignant and Therapeutic Stem Cell Models , Villejuif , France.,b Service d'hématologie , APHP, GHU Paris Sud , Villejuif , France.,c UFR de Médecine Kremlin Bicêtre , Univ. P.Sud, Univ. Paris Saclay , Le Kremlin Bicêtre , France
| | - Hervé Acloque
- a Inserm, UMRS935 ESTeam Paris Sud, Malignant and Therapeutic Stem Cell Models , Villejuif , France.,d UMR1388 GenPhySE , INRA, Université de Toulouse, INRA, INPT, ENVT , Castanet Tolosan , France
| |
Collapse
|
36
|
Sandt C, Feraud O, Bonnet ML, Desterke C, Khedhir R, Flamant S, Bailey CG, Rasko JEJ, Dumas P, Bennaceur-Griscelli A, Turhan AG. Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy. Biochem Biophys Res Commun 2018; 503:1861-1867. [PMID: 30057314 DOI: 10.1016/j.bbrc.2018.07.127] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 07/20/2018] [Accepted: 07/24/2018] [Indexed: 01/07/2023]
Abstract
Despite the major success obtained by the use of tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML), resistances to therapies occur due to mutations in the ABL-kinase domain of the BCR-ABL oncogene. Amongst these mutations, the "gatekeeper" T315I is a major concern as it renders leukemic cells resistant to all licenced TKI except Ponatinib. We report here that Fourier transform infrared (FTIR) microspectroscopy is a powerful methodology allowing rapid and direct identification of a spectral signature in single cells expressing T315I-mutated BCR-ABL. The specificity of this spectral signature is confirmed using a Dox-inducible T315I-mutated BCR-ABL-expressing human UT-7 cells as well as in murine embryonic stem cells. Transcriptome analysis of UT-7 cells expressing BCR-ABL as compared to BCR-ABL T315I clearly identified a molecular signature which could be at the origin of the generation of metabolic changes giving rise to the spectral signature. Thus, these results suggest that this new methodology can be applied to the identification of leukemic cells harbouring the T315I mutation at the single cell level and could represent a novel early detection tool of mutant clones. It could also be applied to drug screening strategies to target T315I-mutated leukemic cells.
Collapse
MESH Headings
- Animals
- Cell Line
- Fusion Proteins, bcr-abl/genetics
- Fusion Proteins, bcr-abl/metabolism
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Mice
- Mutation
- Spectroscopy, Fourier Transform Infrared
Collapse
Affiliation(s)
| | | | | | | | | | | | - Charles G Bailey
- Gene and Stem Cell Therapy Program, Centenary Institute, University of Sydney, Locked Bag No 6, Newtown, NSW, 2042, Australia; Sydney Medical School, University of Sydney, 2006, NSW, Australia
| | - John E J Rasko
- Gene and Stem Cell Therapy Program, Centenary Institute, University of Sydney, Locked Bag No 6, Newtown, NSW, 2042, Australia; Sydney Medical School, University of Sydney, 2006, NSW, Australia; Cell and Molecular Therapies, Royal Prince Alfred Hospital, Camperdown, 2052, NSW, Australia
| | - Paul Dumas
- SOLEIL Synchrotron, Saint Aubin, 91192, Gif sur Yvette, France
| | - Annelise Bennaceur-Griscelli
- INSERM UMR_S_935, Campus CNRS, Villejuif, France; Department of Hematology, Paris Sud Hematology Institute, AP-HP Hôpital Paul Brousse, Villejuif, France; INGESTEM National Pluripotent Stem Cell Infrastructure, University Paris Sud 11, Villejuif, France
| | - Ali G Turhan
- INSERM UMR_S_935, Campus CNRS, Villejuif, France; Department of Hematology, Paris Sud Hematology Institute, AP-HP Hôpital Paul Brousse, Villejuif, France; INGESTEM National Pluripotent Stem Cell Infrastructure, University Paris Sud 11, Villejuif, France.
| |
Collapse
|
37
|
Gentil M, Hugues P, Desterke C, Telliam G, Sloma I, Souza LEB, Baykal S, Artus J, Griscelli F, Guerci A, Johnson-Ansah H, Foudi A, Bennaceur-Griscelli A, Turhan AG. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML). PLoS One 2018; 13:e0200923. [PMID: 30091999 PMCID: PMC6084853 DOI: 10.1371/journal.pone.0200923] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2018] [Accepted: 07/05/2018] [Indexed: 12/15/2022] Open
Abstract
Aryl Hydrocarbon Receptor (AHR) is an ubiquitous basic helix-loop-helix transcription factor, which is ligand-activated and involved in numerous biological processes including cell division, cell quiescence and inflammation. It has been shown that AHR is involved in normal hematopoietic progenitor proliferation in human cells. In addition, loss of AHR in knockout mice is accompanied by a myeloproliferative syndrome-like disease, suggesting a role of AHR in hematopoietic stem cell (HSC) maintenance. To study the potential role of AHR pathway in CML progenitors and stem cells, we have first evaluated the expression of AHR in UT-7 cell line expressing BCR-ABL. AHR expression was highly reduced in UT-7 cell expressing BCR-ABL as compared to controls. AHR transcript levels, quantified in primary peripheral blood CML cells at diagnosis (n = 31 patients) were found to be significantly reduced compared to healthy controls (n = 15). The use of StemRegenin (SR1), an AHR antagonist, induced a marked expansion of total leukemic cells and leukemic CD34+ cells by about 4- and 10-fold respectively. SR1-treated CML CD34+ cells generated more colony-forming cells and long-term culture initiating cell (LTC-IC)-derived progenitors as compared to non-SR1-treated counterparts. Conversely, treatment of CML CD34+ cells with FICZ, a natural agonist of AHR, induced a 3-fold decrease in the number of CD34+ cells in culture after 7 days. Moreover, a 4-day FICZ treatment was sufficient to significantly reduce the clonogenic potential of CML CD34+ cells and this effect was synergized by Imatinib and Dasatinib treatments. Similarly, a 3-day FICZ treatment contributed to hinder significantly the number of LTC-IC-derived progenitors without synergistic effect with Imatinib. The analysis of molecular circuitry of AHR signaling in CML showed a transcriptional signature in CML derived CD34+ CD38- primitive cells with either low or high levels of AHR, with an upregulation of myeloid genes involved in differentiation in the "AHR low" fraction and an upregulation of genes involved in stem cell maintenance in the "AHR high" fraction. In conclusion, these findings demonstrate for the first time that down-regulation of AHR expression, a major cell cycle regulator, is involved in the myeloproliferative phenotype associated with CML. AHR agonists inhibit clonogenic and LTC-IC-derived progenitor growth and they could be used in leukemic stem cell targeting in CML.
Collapse
MESH Headings
- Basic Helix-Loop-Helix Transcription Factors/agonists
- Basic Helix-Loop-Helix Transcription Factors/genetics
- Basic Helix-Loop-Helix Transcription Factors/metabolism
- Carbazoles/pharmacology
- Case-Control Studies
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Fusion Proteins, bcr-abl/genetics
- Fusion Proteins, bcr-abl/metabolism
- Gene Expression Regulation, Neoplastic/drug effects
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism
- Neoplastic Stem Cells/drug effects
- Neoplastic Stem Cells/metabolism
- Neoplastic Stem Cells/pathology
- Purines/pharmacology
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- RNA, Neoplasm/genetics
- RNA, Neoplasm/metabolism
- Receptors, Aryl Hydrocarbon/agonists
- Receptors, Aryl Hydrocarbon/genetics
- Receptors, Aryl Hydrocarbon/metabolism
- Signal Transduction/drug effects
- Tumor Stem Cell Assay
Collapse
Affiliation(s)
- Melanie Gentil
- Inserm U935, Villejuif, France
- University Paris Sud, Faculty of Medicine, Le Kremlin Bicêtre, France
| | - Patricia Hugues
- Inserm U935, Villejuif, France
- University Paris Sud, Faculty of Medicine, Le Kremlin Bicêtre, France
- Service d’Hématologie, Hôpital Bicêtre and Paul Brousse, Le Kremlin Bicêtre and Villejuif, France
| | - Christophe Desterke
- Inserm U935, Villejuif, France
- University Paris Sud, Faculty of Medicine, Le Kremlin Bicêtre, France
| | - Gladys Telliam
- Inserm U935, Villejuif, France
- University Paris Sud, Faculty of Medicine, Le Kremlin Bicêtre, France
| | - Ivan Sloma
- Inserm U935, Villejuif, France
- University Paris Sud, Faculty of Medicine, Le Kremlin Bicêtre, France
- Service d’Hématologie, Hôpital Bicêtre and Paul Brousse, Le Kremlin Bicêtre and Villejuif, France
| | | | - Seda Baykal
- Inserm U935, Villejuif, France
- Dokuz Eylul University Medical School, Medical Biology and Genetics Dept, Izmir, Turkey
| | - Jerome Artus
- Inserm U935, Villejuif, France
- University Paris Sud, Faculty of Medicine, Le Kremlin Bicêtre, France
| | | | | | | | | | - Annelise Bennaceur-Griscelli
- Inserm U935, Villejuif, France
- University Paris Sud, Faculty of Medicine, Le Kremlin Bicêtre, France
- Service d’Hématologie, Hôpital Bicêtre and Paul Brousse, Le Kremlin Bicêtre and Villejuif, France
- Institut Federatif d’Hématologie Paris Sud (IFHIPS), APHP and Service d’Hématologie Bicêtre and Paul Brousse, Villejuif, France
| | - Ali G. Turhan
- Inserm U935, Villejuif, France
- University Paris Sud, Faculty of Medicine, Le Kremlin Bicêtre, France
- Service d’Hématologie, Hôpital Bicêtre and Paul Brousse, Le Kremlin Bicêtre and Villejuif, France
- Institut Federatif d’Hématologie Paris Sud (IFHIPS), APHP and Service d’Hématologie Bicêtre and Paul Brousse, Villejuif, France
- * E-mail:
| |
Collapse
|
38
|
Desterke C, Voldoire M, Bonnet ML, Sorel N, Pagliaro S, Rahban H, Bennaceur-Griscelli A, Cayssials E, Chomel JC, Turhan AG. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML). Exp Hematol 2018; 64:71-83.e8. [DOI: 10.1016/j.exphem.2018.04.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Revised: 04/25/2018] [Accepted: 04/27/2018] [Indexed: 01/13/2023]
|
39
|
M'kacher R, Cuceu C, Al Jawhari M, Morat L, Frenzel M, Shim G, Lenain A, Hempel WM, Junker S, Girinsky T, Colicchio B, Dieterlen A, Heidingsfelder L, Borie C, Oudrhiri N, Bennaceur-Griscelli A, Moralès O, Renaud S, Van de Wyngaert Z, Jeandidier E, Delhem N, Carde P. The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes. Cancers (Basel) 2018; 10:E169. [PMID: 29848986 PMCID: PMC6025489 DOI: 10.3390/cancers10060169] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 05/18/2018] [Accepted: 05/25/2018] [Indexed: 11/16/2022] Open
Abstract
Background: We analyzed telomere maintenance mechanisms (TMMs) in lymph node samples from HL patients treated with standard therapy. The TMMs correlated with clinical outcomes of patients. Materials and Methods: Lymph node biopsies obtained from 38 HL patients and 24 patients with lymphadenitis were included in this study. Seven HL cell lines were used as in vitro models. Telomerase activity (TA) was assessed by TRAP assay and verified through hTERT immunofluorescence expression; alternative telomere lengthening (ALT) was also assessed, along with EBV status. Results: Both TA and ALT mechanisms were present in HL lymph nodes. Our findings were reproduced in HL cell lines. The highest levels of TA were expressed in CD30-/CD15- cells. Small cells were identified with ALT and TA. Hodgkin and Reed Sternberg cells contained high levels of PML bodies, but had very low hTERT expression. There was a significant correlation between overall survival (p < 10-3), event-free survival (p < 10-4), and freedom from progression (p < 10-3) and the presence of an ALT profile in lymph nodes of EBV+ patients. Conclusion: The presence of both types of TMMs in HL lymph nodes and in HL cell lines has not previously been reported. TMMs correlate with the treatment outcome of EBV+ HL patients.
Collapse
Affiliation(s)
- Radhia M'kacher
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
- Cell Environment, DNA Damages R&D, Oncology Section, 75020 Paris, France.
| | - Corina Cuceu
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Mustafa Al Jawhari
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Luc Morat
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Monika Frenzel
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Grace Shim
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Aude Lenain
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - William M Hempel
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, DK-8000 Aarhus C, Denmark.
| | - Theodore Girinsky
- Department of Radiation Therapy, Gustave Roussy Cancer Campus, 94808 Villejuif, France.
| | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | | | - Claire Borie
- Université Paris Sud, Service d'hématologie moléculaire et cytogénétique Paul brousse CHU paris Sud, Inserm UMRS935, 94800 Villejuif, France.
| | - Noufissa Oudrhiri
- Université Paris Sud, Service d'hématologie moléculaire et cytogénétique Paul brousse CHU paris Sud, Inserm UMRS935, 94800 Villejuif, France.
| | - Annelise Bennaceur-Griscelli
- Université Paris Sud, Service d'hématologie moléculaire et cytogénétique Paul brousse CHU paris Sud, Inserm UMRS935, 94800 Villejuif, France.
| | - Olivier Moralès
- CNRS, Institut Pasteur de Lille, UMR 8161-Immunoregulation of Virus-induced Cancers Team, F-59000 Lille, France.
| | - Sarah Renaud
- CNRS, Institut Pasteur de Lille, UMR 8161-Immunoregulation of Virus-induced Cancers Team, F-59000 Lille, France.
| | - Zoé Van de Wyngaert
- CHRU Lille Service des Maladies du Sang, Hopital Huriez, 59000 Lille, France.
| | - Eric Jeandidier
- Service de génétique, Groupe hospitalier de la région de Mulhouse Sud-Alsace, 68093 Mulhouse, France.
| | - Nadira Delhem
- CNRS, Institut Pasteur de Lille, UMR 8161-Immunoregulation of Virus-induced Cancers Team, F-59000 Lille, France.
| | - Patrice Carde
- Department of Medicine, Gustave Roussy Cancer Campus, 94808 Villejuif, France.
| |
Collapse
|
40
|
Girerd S, Tosca L, Herault O, Vignon C, Biard D, Aggoune D, Dkhissi F, Bonnet ML, Sorel N, Desterke C, Bennaceur-Griscelli A, Tachdjian G, Guilhot F, Guilhot J, Chomel JC, Turhan AG. Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells. Biochem Biophys Res Commun 2018; 498:715-722. [DOI: 10.1016/j.bbrc.2018.03.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2018] [Accepted: 03/05/2018] [Indexed: 01/12/2023]
|
41
|
Griscelli F, Ezanno H, Soubeyrand M, Feraud O, Oudrhiri N, Bonnefond A, Turhan AG, Froguel P, Bennaceur-Griscelli A. Generation of an induced pluripotent stem cell (iPSC) line from a patient with maturity-onset diabetes of the young type 3 (MODY3) carrying a hepatocyte nuclear factor 1-alpha (HNF1A) mutation. Stem Cell Res 2018; 29:56-59. [PMID: 29597128 DOI: 10.1016/j.scr.2018.02.017] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2017] [Revised: 02/27/2018] [Accepted: 02/28/2018] [Indexed: 11/29/2022] Open
Abstract
Heterozygous non-synonymous (p.S142F) mutation in HNF1A leads to maturity-onset diabetes of the young (MODY) type 3, which is a subtype of dominant inherited young-onset non-autoimmune diabetes due to the defect of insulin secretion from pancreatic beta cells. We generated induced pluripotent stem cells (iPSCs) from a patient with HNF1A p.S142F mutation. Cells from this patient, which were reprogrammed by non-integrative viral transduction had normal karyotype, harboured the HNF1A p.S142F mutation, expressed pluripotency hallmarks.
Collapse
Affiliation(s)
- Frank Griscelli
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Paris-Saclay University, Villejuif 94800, France; UMR-S 935, INSERM, University Paris Sud, Villejuif 94800, France; Gustave Roussy Institut, Department of Biopathology, Villejuif 94800, France; Paris Descartes University, Faculty Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France.
| | - Hélène Ezanno
- CNRS-UMR8199, Institut Pasteur de Lille, Lille, France; Lille University, Lille, France
| | - Mathis Soubeyrand
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Paris-Saclay University, Villejuif 94800, France; UMR-S 935, INSERM, University Paris Sud, Villejuif 94800, France
| | - Olivier Feraud
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Paris-Saclay University, Villejuif 94800, France; UMR-S 935, INSERM, University Paris Sud, Villejuif 94800, France
| | - Noufissa Oudrhiri
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Paris-Saclay University, Villejuif 94800, France; UMR-S 935, INSERM, University Paris Sud, Villejuif 94800, France
| | - Amélie Bonnefond
- CNRS-UMR8199, Institut Pasteur de Lille, Lille, France; Lille University, Lille, France
| | - Ali G Turhan
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Paris-Saclay University, Villejuif 94800, France; UMR-S 935, INSERM, University Paris Sud, Villejuif 94800, France; Division of Hematology, APHP-Paris Sud University, Le Kremlin Bicêtre 94275, Villejuif 94800, France; Paris Sud University, UPsud, Faculty of Medicine, Le Kremlin Bicêtre 94275, France
| | - Philippe Froguel
- CNRS-UMR8199, Institut Pasteur de Lille, Lille, France; Lille University, Lille, France; Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, London, United Kingdom
| | - Annelise Bennaceur-Griscelli
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Paris-Saclay University, Villejuif 94800, France; UMR-S 935, INSERM, University Paris Sud, Villejuif 94800, France; Division of Hematology, APHP-Paris Sud University, Le Kremlin Bicêtre 94275, Villejuif 94800, France; Paris Sud University, UPsud, Faculty of Medicine, Le Kremlin Bicêtre 94275, France
| |
Collapse
|
42
|
Chomel JC, Bonnet ML, Sorel N, Sloma I, Bennaceur-Griscelli A, Rea D, Legros L, Marfaing-Koka A, Bourhis JH, Ame S, Guerci-Bresler A, Rousselot P, Turhan AG. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget 2018; 7:35293-301. [PMID: 27167108 PMCID: PMC5085229 DOI: 10.18632/oncotarget.9182] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 04/10/2016] [Indexed: 11/25/2022] Open
Abstract
During the last decade, the use of tyrosine kinase inhibitor (TKI) therapy has modified the natural history of chronic myeloid leukemia (CML) allowing an increase of the overall and disease-free survival, especially in patients in whom molecular residual disease becomes undetectable. However, it has been demonstrated that BCR-ABL1- expressing leukemic stem cells (LSCs) persist in patients in deep molecular response. It has also been shown that the discontinuation of Imatinib leads to a molecular relapse in the majority of cases. To determine a possible relationship between these two phenomena, we have evaluated by clonogenic and long-term culture initiating cell (LTC-IC) assays, the presence of BCR-ABL1-expressing LSCs in marrow samples from 21 patients in deep molecular response for three years after TKI therapy (mean duration seven years). LSCs were detected in 4/21 patients. Discontinuation of TKI therapy in 13/21 patients led to a rapid molecular relapse in five patients (4 without detectable LSCs and one with detectable LSCs). No relapse occurred in the eight patients still on TKI therapy, whether LSCs were detectable or not. Thus, this study demonstrates for the first time the in vivo efficiency of TKIs, both in the progenitor and the LSC compartments. It also confirms the persistence of leukemic stem cells in patients in deep molecular response, certainly at the origin of relapses. Finally, it emphasizes the difficulty of detecting residual LSCs due to their rarity and their low BCR-ABL1 mRNA expression.
Collapse
Affiliation(s)
- Jean Claude Chomel
- Laboratoire de Cancérologie Biologique, CHU de Poitiers, Poitiers, France.,INSERM U935, Poitiers, France
| | | | - Nathalie Sorel
- Laboratoire de Cancérologie Biologique, CHU de Poitiers, Poitiers, France.,INSERM U935, Poitiers, France
| | - Ivan Sloma
- Service d'Hématologie Biologique, Hôpital Paul Brousse, Villejuif, France.,INSERM U935, Villejuif, France.,Université Paris Sud, Le Kremlin-Bicêtre, France
| | - Annelise Bennaceur-Griscelli
- Service d'Hématologie Biologique, Hôpital Paul Brousse, Villejuif, France.,INSERM U935, Villejuif, France.,Université Paris Sud, Le Kremlin-Bicêtre, France
| | - Delphine Rea
- Service d'Hématologie Adulte, Hôpital Saint Louis, Paris, France.,INSERM UMRS-1160, IUH-Université Paris Diderot-Paris 7, Paris, France
| | - Laurence Legros
- Service d'Hématologie Clinique, Hôpital l'Archet, Nice, France
| | - Anne Marfaing-Koka
- Service d'Hématologie Biologique, Hôpital Antoine Béclère, Clamart, France
| | - Jean-Henri Bourhis
- Service d'Hématologie Biologique, Hôpital Antoine Béclère, Clamart, France.,Service d'Hématologie-Greffe de Moelle, Institut Gustave Roussy, Villejuif, France
| | - Shanti Ame
- Département d'Hématologie et Oncologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | | | - Philippe Rousselot
- Service d'Hématologie et Oncologie, Centre Hospitalier de Versailles, Versailles, France.,EA4340, Université Versailles-Saint Quentin en Yvelines, Université Paris-Saclay, France
| | - Ali G Turhan
- INSERM U935, Poitiers, France.,Service d'Hématologie Biologique, Hôpital Paul Brousse, Villejuif, France.,INSERM U935, Villejuif, France.,Université Paris Sud, Le Kremlin-Bicêtre, France.,Service d'Hématologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| |
Collapse
|
43
|
Hadoux J, Desterke C, Féraud O, Guibert M, De Rose RF, Opolon P, Divers D, Gobbo E, Griscelli F, Schlumberger M, Bennaceur-Griscelli A, Turhan AG. Transcriptional landscape of a RET C634Y-mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of EGR1 transcriptional program in the development of multiple endocrine neoplasia type 2A-associated cancers. Stem Cell Res 2017; 26:8-16. [PMID: 29197744 DOI: 10.1016/j.scr.2017.11.015] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2017] [Revised: 11/14/2017] [Accepted: 11/20/2017] [Indexed: 12/15/2022] Open
Abstract
MEN2A is a hereditary cancer-predisposing syndrome that affects patients with germline RET mutations. The effects of this oncogenic tyrosine kinase in the context of primitive stem cells are not known. In order to study these events, we generated a MEN2A induced Pluripotent Stem Cell (iPSC) line from a patient with RET mutation and an isogenic counterpart by CRISPR-Cas9 correction of the mutation. Whole exome sequencing of iPSC before and after CRISPR-Cas9 genome edition revealed no major exonic off target effect of the CRISPR correction. However, an integrative differential gene expression analysis of iPSC with oncogenic RETC634Y and its gene-corrected iPSC with RETY634C as well as RETwt iPSCs revealed activation of the Early Growth Response 1 (EGR1) transcriptional program in RET-mutated iPSC, a pathway shown to be involved in RET-induced oncogenesis. These data constitute the first proof of concept of the feasibility of the use of an iPSC and its genome-corrected counterpart to unravel the molecular mechanisms underlying the development of the hereditary MEN2A cancer predisposing syndrome.
Collapse
Affiliation(s)
- Julien Hadoux
- Inserm UMRS 935, Université Paris Sud, Villejuif, France; Gustave Roussy, Department of Nuclear medicine and Endocrine Oncology, 94800 Villejuif, France
| | | | - Olivier Féraud
- Inserm UMRS 935, Université Paris Sud, Villejuif, France; ESTeam Paris Sud, Infrastructure INGESTEM, Villejuif, France
| | - Mathieu Guibert
- Inserm UMRS 935, Université Paris Sud, Villejuif, France; ESTeam Paris Sud, Infrastructure INGESTEM, Villejuif, France
| | - Roberta Francesca De Rose
- Inserm UMRS 935, Université Paris Sud, Villejuif, France; Department of Health Sciences, University of Catanzaro, Catanzaro, Italy
| | - Paule Opolon
- Gustave Roussy, Laboratoire de Pathologie Expérimentale, F-94800 Villejuif, France
| | - Dominique Divers
- Inserm UMRS 935, Université Paris Sud, Villejuif, France; ESTeam Paris Sud, Infrastructure INGESTEM, Villejuif, France
| | - Emilie Gobbo
- ESTeam Paris Sud, Infrastructure INGESTEM, Villejuif, France
| | - Frank Griscelli
- Inserm UMRS 935, Université Paris Sud, Villejuif, France; ESTeam Paris Sud, Infrastructure INGESTEM, Villejuif, France; Paris Descartes University, & Gustave Roussy, Villejuif, France
| | - Martin Schlumberger
- Gustave Roussy, Laboratoire de Pathologie Expérimentale, F-94800 Villejuif, France
| | - Annelise Bennaceur-Griscelli
- Inserm UMRS 935, Université Paris Sud, Villejuif, France; ESTeam Paris Sud, Infrastructure INGESTEM, Villejuif, France; APHP, Division of Hematology-of Paris Sud University Hospitals, University Paris Sud, Le Kremlin Bicêtre, France
| | - Ali G Turhan
- Inserm UMRS 935, Université Paris Sud, Villejuif, France; ESTeam Paris Sud, Infrastructure INGESTEM, Villejuif, France; APHP, Division of Hematology-of Paris Sud University Hospitals, University Paris Sud, Le Kremlin Bicêtre, France.
| |
Collapse
|
44
|
Bennaceur-Griscelli A, Hadoux J, Féraud O, Opolon P, Divers D, Gobbo E, Schlumberger M, Griscelli F, Turhan AG. Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with "highest risk" RET mutation. Stem Cell Res 2017; 23:154-157. [PMID: 28925363 DOI: 10.1016/j.scr.2017.07.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2017] [Accepted: 07/20/2017] [Indexed: 10/19/2022] Open
Abstract
Multiple Endocrine Neoplasia Type 2B (MEN2B) is a cancer-predisposing syndrome that affects patients with germline RET mutations. The clinical spectrum of the syndrome includes medullary thyroid carcinoma (MTC) and pheochromocytoma. Currently, there is no satisfactory model recapitulating all the features of the disease especially at the level of stem cells. We generated induced pluripotent stem cells (iPSCs) from a patient with RET mutation at codon 918 who developed pheochromocytoma and MTC. These iPSC had normal karyotype, harboured the RETM918T mutation and expressed pluripotency hallmarks. A comprehensive pathological assessment of teratoma was performed after injection in immunodeficient mice.
Collapse
Affiliation(s)
- A Bennaceur-Griscelli
- INSERM U935, Université Paris Sud, 94800, Villejuif, France; ESTeam Paris Sud, INSERM U935, Université Paris Sud, Université Paris-Saclay, 94800, Villejuif, France; INGESTEM National IPSC Infrastructure, 94800 Villejuif, France; Division of Hematology, Paris Sud University Hospitals, Le Kremlin Bicêtre 94275, France; Division of Hematology, Paris Sud University Hospitals, Villejuif 94800, France
| | - J Hadoux
- INSERM U935, Université Paris Sud, 94800, Villejuif, France; Gustave Roussy, Department of Nuclear Medicine and Endocrine Oncology, 94800 Villejuif, France.
| | - O Féraud
- INSERM U935, Université Paris Sud, 94800, Villejuif, France; ESTeam Paris Sud, INSERM U935, Université Paris Sud, Université Paris-Saclay, 94800, Villejuif, France.
| | - P Opolon
- Gustave Roussy, Laboratoire de Pathologie Expérimentale, F-94800 Villejuif, France
| | - D Divers
- INSERM U935, Université Paris Sud, 94800, Villejuif, France; ESTeam Paris Sud, INSERM U935, Université Paris Sud, Université Paris-Saclay, 94800, Villejuif, France.
| | - E Gobbo
- INSERM U935, Université Paris Sud, 94800, Villejuif, France; ESTeam Paris Sud, INSERM U935, Université Paris Sud, Université Paris-Saclay, 94800, Villejuif, France
| | - M Schlumberger
- Gustave Roussy, Department of Nuclear Medicine and Endocrine Oncology, 94800 Villejuif, France.
| | - F Griscelli
- INSERM U935, Université Paris Sud, 94800, Villejuif, France; ESTeam Paris Sud, INSERM U935, Université Paris Sud, Université Paris-Saclay, 94800, Villejuif, France; INGESTEM National IPSC Infrastructure, 94800 Villejuif, France.
| | - A G Turhan
- INSERM U935, Université Paris Sud, 94800, Villejuif, France; ESTeam Paris Sud, INSERM U935, Université Paris Sud, Université Paris-Saclay, 94800, Villejuif, France; INGESTEM National IPSC Infrastructure, 94800 Villejuif, France; Division of Hematology, Paris Sud University Hospitals, Le Kremlin Bicêtre 94275, France; Division of Hematology, Paris Sud University Hospitals, Villejuif 94800, France.
| |
Collapse
|
45
|
Sloma I, Mitjavila-Garcia MT, Feraud O, Griscelli F, Oudrhiri N, El Marsafy S, Gobbo E, Divers D, Proust A, Smadja DM, Desterke C, Carles A, Ma Y, Hirst M, Marra MA, Eaves CJ, Bennaceur-Griscelli A, Turhan AG. Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia. Exp Hematol 2017; 53:48-58. [DOI: 10.1016/j.exphem.2017.05.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2017] [Revised: 05/20/2017] [Accepted: 05/22/2017] [Indexed: 01/17/2023]
|
46
|
Aggoune D, Sorel N, Bonnet ML, Goujon JM, Tarte K, Hérault O, Domenech J, Réa D, Legros L, Johnson-Ansa H, Rousselot P, Cayssials E, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG. Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs). Leuk Res 2017; 60:94-102. [PMID: 28772207 DOI: 10.1016/j.leukres.2017.07.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 07/01/2017] [Accepted: 07/25/2017] [Indexed: 01/05/2023]
Abstract
Although it has been well-demonstrated that bone marrow mesenchymal stromal cells (MSCs) from CML patients do not belong to the Ph1-positive clone, there is growing evidence that they could play a role in the leukemogenesis process or the protection of leukemic stem cells from the effects of tyrosine kinase inhibitors (TKIs). The aim of the present study was to identify genes differentially expressed in MSCs isolated from CML patients at diagnosis (CML-MSCs) as compared to MSCs from healthy controls. Using a custom gene-profiling assay, we identified six genes over-expressed in CML-MSCs (BMP1, FOXO3, MET, MITF, NANOG, PDPN), with the two highest levels being documented for PDPN (PODOPLANIN) and NANOG. To determine whether this aberrant signature persisted in patients in deep molecular response induced by TKIs, we analyzed MSCs derived from such patients (MR-MSCs). This analysis showed that, despite the deep molecular responses, BMP1, MET, MITF, NANOG, and PDPN mRNA were upregulated in MR-MSCs. Moreover, BMP1, MITF, and NANOG mRNA expressions in MR-MSCs were found to be intermediate between control MSCs and CML-MSCs. These results suggest that CML-MSCs exhibit an abnormal gene expression pattern which might have been established during the leukemogenic process and persist in patients in deep molecular response.
Collapse
Affiliation(s)
| | - Nathalie Sorel
- INSERM, U935, F-86000 Poitiers, France; CHU de Poitiers, Service de Cancérologie Biologique, F-86021 Poitiers, France
| | | | - Jean-Michel Goujon
- CHU de Poitiers, Service d'Anatomie et cytologie pathologiques, F-86021 Poitiers, France; INSERM, U1082, F-86021 Poitiers, France
| | | | - Olivier Hérault
- CHU de Tours, Service d'Hématologie Biologique, F-37032 Tours, France; CNRS UMR 7292, équipe LNOx, Université François Rabelais, F-37032 Tours, France
| | - Jorge Domenech
- CHU de Tours, Service d'Hématologie Biologique, F-37032 Tours, France; CNRS UMR 7292, équipe LNOx, Université François Rabelais, F-37032 Tours, France
| | - Delphine Réa
- Hôpital Saint Louis, Service d'Hématologie Adulte, F-75000 Paris, France; INSERM, UMRS-1160, IUH-Université Paris Diderot-Paris 7, F-75000 Paris, France
| | - Laurence Legros
- Hôpital l'Archet, Service d'Hématologie Clinique, F-06202 Nice, France
| | | | - Philippe Rousselot
- Centre Hospitalier de Versailles, Service d'Hématologie et Oncologie, F-78150 Le Chesnay, France; EA4340, Université Versailles-Saint Quentin en Yvelines, Université Paris-Saclay, France
| | - Emilie Cayssials
- INSERM, CIC-P 0802, F-86000 Poitiers, France; CHU de Poitiers, Service d'Oncologie Hématologique et Thérapie Cellulaire, F-86000, Poitiers, France
| | | | - Annelise Bennaceur-Griscelli
- Hôpital Paul Brousse, Service d'Hématologie Biologique, F-94800 Villejuif, France; NSERM U935, F-94807 Villejuif, France; Université Paris Sud, F-94270 Le Kremlin-Bicêtre, France
| | - Jean-Claude Chomel
- INSERM, U935, F-86000 Poitiers, France; CHU de Poitiers, Service de Cancérologie Biologique, F-86021 Poitiers, France
| | - Ali G Turhan
- INSERM, U935, F-86000 Poitiers, France; Hôpital Paul Brousse, Service d'Hématologie Biologique, F-94800 Villejuif, France; NSERM U935, F-94807 Villejuif, France; Université Paris Sud, F-94270 Le Kremlin-Bicêtre, France; Hôpital Bicêtre, Service d'Hématologie Biologique, F-94270 Le Kremlin Bicêtre, France.
| |
Collapse
|
47
|
Griscelli F, Feraud O, Ernault T, Oudrihri N, Turhan AG, Bonnefond A, Froguel P, Bennaceur-Griscelli A. Generation of an induced pluripotent stem cell (iPSC) line from a patient with maturity-onset diabetes of the young type 13 (MODY13) with a the potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11) mutation. Stem Cell Res 2017; 23:178-181. [PMID: 28925365 DOI: 10.1016/j.scr.2017.07.023] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Revised: 07/09/2017] [Accepted: 07/20/2017] [Indexed: 10/19/2022] Open
Abstract
Heterozygous activating mutation (p.Glu227Lys) in KCNJ11 leads to maturity-onset diabetes of the young (MODY) type 13, that is a subtype of dominant inherited young-onset non-autoimmune diabetes due to a primary defect in pancreatic beta cells. We generated induced pluripotent stem cells (iPSCs) from a patient with KCNJ11p.Glu227Lys mutation who developed MODY at 13years old. KCNJ11p.Glu227Lys-mutated cells that were reprogrammed by non-integrative viral transduction had normal karyotype, harboured the KCNJ11p.Glu227Lys mutation, expressed pluripotency hallmarks and had the differentiation capacity into the three germ layers.
Collapse
Affiliation(s)
- Frank Griscelli
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Université Paris-Saclay, 94800 Villejuif, France; Division of Hematology, APHP-Paris Sud University hospitals, Le Kremlin Bicêtre 94275 and Villejuif, 94800, France; Gustave Roussy Institut, Department of Biopathology, 94800 Villejuif, France; University Paris Descartes, Faculty Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France.
| | - Olivier Feraud
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Université Paris-Saclay, 94800 Villejuif, France; Division of Hematology, APHP-Paris Sud University hospitals, Le Kremlin Bicêtre 94275 and Villejuif, 94800, France
| | - Tony Ernault
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Université Paris-Saclay, 94800 Villejuif, France; Division of Hematology, APHP-Paris Sud University hospitals, Le Kremlin Bicêtre 94275 and Villejuif, 94800, France
| | - Noufissa Oudrihri
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Université Paris-Saclay, 94800 Villejuif, France; Division of Hematology, APHP-Paris Sud University hospitals, Le Kremlin Bicêtre 94275 and Villejuif, 94800, France; Division of Hematology, APHP-Paris Sud University Hospitals, Le Kremlin Bicêtre 94275, France
| | - Ali G Turhan
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Université Paris-Saclay, 94800 Villejuif, France; Division of Hematology, APHP-Paris Sud University hospitals, Le Kremlin Bicêtre 94275 and Villejuif, 94800, France; Division of Hematology, APHP-Paris Sud University Hospitals, Le Kremlin Bicêtre 94275, France; University Paris Sud, UPsud, Faculty of Medicine, Le Kremlin Bicêtre 94275, France
| | - Amélie Bonnefond
- CNRS-UMR8199, Lille Pasteur Institute, Lille, France; Lille Nord de France University, Lille, France; Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, London, United Kingdom
| | - Philippe Froguel
- CNRS-UMR8199, Lille Pasteur Institute, Lille, France; Lille Nord de France University, Lille, France; Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, London, United Kingdom
| | - Annelise Bennaceur-Griscelli
- ESTeam Paris Sud, INGESTEM National IPSC Infrastructure, UPSud, Université Paris-Saclay, 94800 Villejuif, France; Division of Hematology, APHP-Paris Sud University hospitals, Le Kremlin Bicêtre 94275 and Villejuif, 94800, France; Division of Hematology, APHP-Paris Sud University Hospitals, Le Kremlin Bicêtre 94275, France; University Paris Sud, UPsud, Faculty of Medicine, Le Kremlin Bicêtre 94275, France
| |
Collapse
|
48
|
Kaddour A, Colicchio B, Buron D, El Maalouf E, Laplagne E, Borie C, Ricoul M, Lenain A, Hempel WM, Morat L, Al Jawhari M, Cuceu C, Heidingsfelder L, Jeandidier E, Deschênes G, Dieterlen A, El May M, Girinsky T, Bennaceur-Griscelli A, Carde P, Sabatier L, M'kacher R. Transmission of Induced Chromosomal Aberrations through Successive Mitotic Divisions in Human Lymphocytes after In Vitro and In Vivo Radiation. Sci Rep 2017; 7:3291. [PMID: 28607452 PMCID: PMC5468351 DOI: 10.1038/s41598-017-03198-7] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 04/24/2017] [Indexed: 11/10/2022] Open
Abstract
The mechanisms behind the transmission of chromosomal aberrations (CA) remain unclear, despite a large body of work and major technological advances in chromosome identification. We reevaluated the transmission of CA to second- and third-division cells by telomere and centromere (TC) staining followed by M-FISH. We scored CA in lymphocytes of healthy donors after in vitro irradiation and those of cancer patients treated by radiation therapy more than 12 years before. Our data demonstrate, for the first time, that dicentric chromosomes (DCs) decreased by approximately 50% per division. DCs with two centromeres in close proximity were more efficiently transmitted, representing 70% of persistent DCs in ≥M3 cells. Only 1/3 of acentric chromosomes (ACs), ACs with four telomeres, and interstitial ACs, were paired in M2 cells and associated with specific DCs configurations. In lymphocytes of cancer patients, 82% of detected DCs were characterized by these specific configurations. Our findings demonstrate the high stability of DCs with two centromeres in close proximity during cell division. The frequency of telomere deletion increased during cell cycle progression playing an important role in chromosomal instability. These findings could be exploited in the follow-up of exposed populations.
Collapse
Affiliation(s)
- Akram Kaddour
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France.,Tunis El Manar University, School of Medicine, Tunis, Tunisia
| | - Bruno Colicchio
- Laboratoire MIPS Groupe IMTI Université de Haute-Alsace, Mulhouse, France
| | - Diane Buron
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Elie El Maalouf
- Laboratoire MIPS Groupe IMTI Université de Haute-Alsace, Mulhouse, France
| | | | - Claire Borie
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, Villejuif, France
| | - Michelle Ricoul
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Aude Lenain
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - William M Hempel
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Luc Morat
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Mustafa Al Jawhari
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Corina Cuceu
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | | | - Eric Jeandidier
- Service de Génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, 68070, Mulhouse, France
| | | | - Alain Dieterlen
- Laboratoire MIPS Groupe IMTI Université de Haute-Alsace, Mulhouse, France
| | - Michèle El May
- Tunis El Manar University, School of Medicine, Tunis, Tunisia
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
| | | | - Patrice Carde
- Department of Hematology, Gustave Roussy cancer Campus, Villejuif, France
| | - Laure Sabatier
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Radhia M'kacher
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France. .,Cell Environment, Paris, France.
| |
Collapse
|
49
|
Garcia M, Chomel JC, Mustapha P, Tran CT, Garnier M, Paris I, Quellard N, Godet J, Cremniter J, Bennaceur-Griscelli A, Lecron JC, Turhan AG, Burucoa C, Bodet C. In vitro culture and phenotypic and molecular characterization of gastric stem cells from human stomach. Helicobacter 2017; 22. [PMID: 27592706 DOI: 10.1111/hel.12351] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
BACKGROUND Human gastric mucosa shows continuous self-renewal via differentiation from stem cells that remain poorly characterized. METHODS We describe an original protocol for culture of gastric stem/progenitor cells from adult human stomach. The molecular characteristics of cells were studied using TaqMan low-density array and qRT-PCR analyses using the well-characterized H1 and H9 embryonic stem cells as reference. Epithelial progenitor cells were challenged with H. pylori to characterize their inflammatory response. RESULTS Resident gastric stem cells expressed specific molecular markers of embryonic stem cells (SOX2, NANOG, and OCT4), as well as others specific to adult stem cells, particularly LGR5 and CD44. We show that gastric stem cells spontaneously differentiate into epithelial progenitor cells that can be challenged with H. pylori. The epithelial progenitor response to H. pylori showed a cag pathogenicity island-dependent induction of matrix metalloproteinases 1 and 3, chemokine (CXCL1, CXCL5, CXCL8, CCL20) and interleukine 33 expression. CONCLUSION This study opens new outlooks for investigation of gastric stem cell biology and pathobiology as well as host-H. pylori interactions.
Collapse
Affiliation(s)
- Magali Garcia
- Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, Université de Poitiers, Poitiers, France.,Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Jean-Claude Chomel
- Centre Hospitalier Universitaire de Poitiers, Poitiers, France.,Inserm U935, Université de Poitiers, Poitiers, France
| | - Pascale Mustapha
- Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, Université de Poitiers, Poitiers, France
| | - Cong Tri Tran
- Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, Université de Poitiers, Poitiers, France.,Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Martine Garnier
- Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, Université de Poitiers, Poitiers, France.,Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Isabelle Paris
- Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, Université de Poitiers, Poitiers, France.,Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | | | - Julie Godet
- Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Julie Cremniter
- Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, Université de Poitiers, Poitiers, France.,Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Annelise Bennaceur-Griscelli
- Inserm U935, Université de Poitiers, Poitiers, France.,Inserm U935, Hôpitaux Universitaires Paris Sud, Hôpital Bicêtre & Paul Brousse, Université Paris-Sud, Villejuif, France
| | - Jean-Claude Lecron
- Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, Université de Poitiers, Poitiers, France.,Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Ali G Turhan
- Inserm U935, Université de Poitiers, Poitiers, France.,Inserm U935, Hôpitaux Universitaires Paris Sud, Hôpital Bicêtre & Paul Brousse, Université Paris-Sud, Villejuif, France
| | - Christophe Burucoa
- Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, Université de Poitiers, Poitiers, France.,Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Charles Bodet
- Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, Université de Poitiers, Poitiers, France
| |
Collapse
|
50
|
Telliam G, Féraud O, Griscelli F, Opolon P, Divers D, Bennaceur-Griscelli A, Turhan A. Generation of an induced pluripotent stem cell line from a patient with chronic myeloid leukemia (CML) resistant to targeted therapies. Stem Cell Res 2016; 17:235-237. [DOI: 10.1016/j.scr.2016.08.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Revised: 07/23/2016] [Accepted: 08/02/2016] [Indexed: 10/21/2022] Open
|